{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":"Activist Defense","value":72},{"name":"Capital Markets","value":26},{"name":"Construction and Procurement","value":40},{"name":"Corporate Governance","value":27},{"name":"Emerging Companies and Venture Capital","value":80},{"name":"Employee Benefits and Executive Compensation","value":28},{"name":"Energy and Infrastructure Projects","value":35},{"name":"Financial Restructuring","value":10},{"name":"Fund Finance","value":134},{"name":"Global Human Capital and Compliance ","value":121},{"name":"Investment Funds and Asset Management","value":78},{"name":"Leveraged Finance","value":29},{"name":"Mergers and Acquisitions (M\u0026A)","value":32},{"name":"Middle East and Islamic Finance and Investment","value":31},{"name":"Private Equity","value":33},{"name":"Public Companies","value":126},{"name":"Real Estate","value":36},{"name":"Structured Finance and Securitization","value":82},{"name":"Tax","value":37},{"name":"Technology Transactions","value":115},{"name":"Government Matters","value":"cg-2"},{"name":"Antitrust","value":1},{"name":"Data, Privacy and Security","value":6},{"name":"Environmental, Health and Safety","value":71},{"name":"FDA and Life Sciences","value":21},{"name":"Government Advocacy and Public Policy","value":23},{"name":"Government Contracts","value":116},{"name":"Healthcare","value":24},{"name":"Innovation Protection","value":135},{"name":"International Trade","value":25},{"name":"National Security and Corporate Espionage","value":110},{"name":"Securities Enforcement and Regulation","value":20},{"name":"Special Matters and Government Investigations","value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":"Antitrust ","value":129},{"name":"Appellate, Constitutional and Administrative Law","value":2},{"name":"Bankruptcy and Insolvency Litigation","value":38},{"name":"Class Action Defense","value":3},{"name":"Commercial Litigation","value":5},{"name":"Corporate and Securities Litigation","value":19},{"name":"E-Discovery","value":7},{"name":"Global Construction and Infrastructure Disputes","value":4},{"name":"Innovation Protection","value":136},{"name":"Intellectual Property","value":13},{"name":"International Arbitration and Litigation","value":14},{"name":"Labor and Employment","value":15},{"name":"Product Liability","value":17},{"name":"Professional Liability","value":18},{"name":"Toxic \u0026 Environmental Torts","value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":"Artificial Intelligence (AI) and Machine Learning","value":133},{"name":"Automotive, Transportation and Mobility","value":106},{"name":"Buy American","value":124},{"name":"Crisis Management","value":111},{"name":"Doing Business in Latin America","value":132},{"name":"Energy Transition","value":131},{"name":"Energy","value":102},{"name":"Environmental Agenda","value":125},{"name":"Environmental, Social and Governance (ESG)","value":127},{"name":"Financial Services","value":107},{"name":"Focus on Women's Health","value":112},{"name":"Food and Beverage","value":105},{"name":"Higher Education","value":109},{"name":"Life Sciences and Healthcare","value":103},{"name":"Russia/Ukraine","value":128},{"name":"Special Purpose Acquisition Companies (SPACs)","value":123},{"name":"Technology","value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"103","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"S","per_page":12,"people":[{"id":426410,"version":1,"owner_type":"Person","owner_id":3373,"payload":{"bio":"\u003cp\u003eDan Sale defends clients in high-stakes government and Congressional investigations, enforcement proceedings, and parallel civil litigation.\u0026nbsp; Concentrating in complex criminal and civil litigation, Dan regularly represents life sciences companies, financial institutions, other highly-regulated companies, and their boards and senior executives in high-profile and sensitive investigations and litigation.\u0026nbsp; Dan has special experience in matters involving: life sciences criminal and civil investigations; Congressional investigations;\u0026nbsp;the False Claims Act; financial crimes, the Foreign Corrupt Practices Act (FCPA);\u0026nbsp; antitrust and market manipulation matters; the securities laws; whistleblower cases; and transnational tax investigations.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDan has special experience in cases involving allegations of off-label promotion and kickbacks in the life sciences industry and represented clients in the three largest Anti-Kickback Statute investigations ever resolved with DOJ.\u0026nbsp; Dan also has special experience in state attorney general investigations, and has personally negotiated quiet resolutions with all 50 state AG offices and the District of Columbia.\u0026nbsp; In addition, Dan has considerable experience defending clients in multi-jurisdictional investigations and litigation conducted cooperatively by United States, European, Middle Eastern, Asian and African authorities\u003c/p\u003e\n\u003cp\u003eThe Special Matters \u0026amp; Government Investigations group has been twice recognized by\u0026nbsp;\u003cem\u003eLaw 360\u003c/em\u003e\u0026nbsp;as the \u0026ldquo;White-Collar Group of the Year\u0026rdquo; and described as \u0026ldquo;the premier firm in this practice area\u0026rdquo; by the\u0026nbsp;\u003cem\u003eU.S. News \u0026amp; World Report/Best Lawyers\u0026rsquo;\u003c/em\u003e\u0026nbsp;\u0026ldquo;Best Law Firms\u0026rdquo; survey.\u003c/p\u003e\n\u003cp\u003eDan began his legal career as a law clerk to the Honorable Richard D. Bennett of the United States District Court for the District of Maryland. \u0026nbsp;He received his J.D. from Georgetown University Law Center, where he was an Editorial Board Member of the Tax Lawyer law journal, and his B.A. in economics from Yale University, where he was a Division I All New England Scholar Athlete lacrosse player.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDan holds Top Secret/SCI security clearances until their expiration.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDan is a regular contributor to the American Bar Association's Criminal Litigation Section's Practice Points publication\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eThe US v. Vascular Solutions Acquittal: Three Lessons for Targets of Off-Label Promotion Enforcement\u003c/em\u003e, Washington Legal Foundation Legal Backgrounder (2016)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eRecent Trends in Health Care Enforcement and Compliance\u003c/em\u003e, Inside the Minds: Health Care Law Enforcement and Compliance (Apastore 2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eThe Future of Off-Label Promotion Enforcement in the Wake of Caronia \u0026mdash; Toward a First Amendment Safe Harbor\u003c/em\u003e, The Sedona Conference Journal, Volume 14 (2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eOff-Label Promotion: The Criminalization of Scientific Exchange\u003c/em\u003e, Pharma Magazine (UK) (2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eFDA as Arbiter of Truth? The First Amendment, Caronia, and the Future of Off-Label Promotion Enforcement\u003c/em\u003e, ABA White Collar Crime (2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eTenure Trap: Third Circuit Joins Sixth in Holding Tenure Buy-out Payments Subject to FICA Taxation in University of Pittsburgh v. United States\u003c/em\u003e, The Tax Lawyer, Volume 63 (2010)\u003c/li\u003e\n\u003c/ul\u003e","slug":"daniel-sale","email":"dsale@kslaw.com","phone":null,"matters":["\u003cp\u003eRepresenting\u0026nbsp;\u003cem\u003epro bono\u003c/em\u003e\u0026nbsp;a former Army Ranger convicted by court martial of murder in Iraq, resulting in a full Presidential pardon.\u003c/p\u003e","\u003cp\u003eRepresenting an individual in connection with the Special Counsel investigation conducted by Robert Mueller.\u003c/p\u003e","\u003cp\u003eRepresenting a global pharmaceutical company in an industry-wide investigation regarding donations to charitable patient assistance foundations.\u003c/p\u003e","\u003cp\u003eSecured a declination of all criminal and civil liability for a global medical device manufacturer in an investigation involving off-label promotion and fraud issues\u003c/p\u003e","\u003cp\u003eRepresented Vascular Solutions, Inc., a publicly traded medical device manufacturer that was indicted on federal criminal charges relating to off-label promotion and acquitted by a jury of all charges after a four week trial in February 2016.\u003c/p\u003e","\u003cp\u003eRepresenting several individual witnesses and targets in connection with domestic and international investigations of foreign exchange (FX) trading, resulting in no charges.\u003c/p\u003e","\u003cp\u003eRepresented leading pharmaceutical manufacturers into off-label promotion issues by the Department of Justice and multiple U.S. Attorneys\u0026rsquo; Offices, the FDA, the Department of Health and Human Services Office of Inspector General, and various state Attorneys General, as well as parallel federal False Claims Act\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;litigation.\u003c/p\u003e","\u003cp\u003eRepresented current and former CEOs, high-level executives, and other individuals in FCPA investigations related to events throughout Latin America, the Middle East, China, Mexico, and Eastern Europe.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":1,"source":"smartTags"},{"id":2,"guid":"2.capabilities","index":2,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":3,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":4,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":5,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":6,"source":"capabilities"},{"id":780,"guid":"780.smart_tags","index":7,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":8,"source":"smartTags"},{"id":20,"guid":"20.capabilities","index":9,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":10,"source":"smartTags"},{"id":5,"guid":"5.capabilities","index":11,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":12,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":13,"source":"capabilities"},{"id":7,"guid":"7.capabilities","index":14,"source":"capabilities"},{"id":1248,"guid":"1248.smart_tags","index":15,"source":"smartTags"}],"is_active":true,"last_name":"Sale","nick_name":"Daniel","clerkships":[{"name":"Law Clerk, Richard D. Bennett, U.S. District Court for the District of Maryland","years_held":"2010-2012"}],"first_name":"Daniel","title_rank":9999,"updated_by":202,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"2010-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"C.","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/daniel-sale-27063baa/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eDan Sale defends clients in high-stakes government and Congressional investigations, enforcement proceedings, and parallel civil litigation.\u0026nbsp; Concentrating in complex criminal and civil litigation, Dan regularly represents life sciences companies, financial institutions, other highly-regulated companies, and their boards and senior executives in high-profile and sensitive investigations and litigation.\u0026nbsp; Dan has special experience in matters involving: life sciences criminal and civil investigations; Congressional investigations;\u0026nbsp;the False Claims Act; financial crimes, the Foreign Corrupt Practices Act (FCPA);\u0026nbsp; antitrust and market manipulation matters; the securities laws; whistleblower cases; and transnational tax investigations.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDan has special experience in cases involving allegations of off-label promotion and kickbacks in the life sciences industry and represented clients in the three largest Anti-Kickback Statute investigations ever resolved with DOJ.\u0026nbsp; Dan also has special experience in state attorney general investigations, and has personally negotiated quiet resolutions with all 50 state AG offices and the District of Columbia.\u0026nbsp; In addition, Dan has considerable experience defending clients in multi-jurisdictional investigations and litigation conducted cooperatively by United States, European, Middle Eastern, Asian and African authorities\u003c/p\u003e\n\u003cp\u003eThe Special Matters \u0026amp; Government Investigations group has been twice recognized by\u0026nbsp;\u003cem\u003eLaw 360\u003c/em\u003e\u0026nbsp;as the \u0026ldquo;White-Collar Group of the Year\u0026rdquo; and described as \u0026ldquo;the premier firm in this practice area\u0026rdquo; by the\u0026nbsp;\u003cem\u003eU.S. News \u0026amp; World Report/Best Lawyers\u0026rsquo;\u003c/em\u003e\u0026nbsp;\u0026ldquo;Best Law Firms\u0026rdquo; survey.\u003c/p\u003e\n\u003cp\u003eDan began his legal career as a law clerk to the Honorable Richard D. Bennett of the United States District Court for the District of Maryland. \u0026nbsp;He received his J.D. from Georgetown University Law Center, where he was an Editorial Board Member of the Tax Lawyer law journal, and his B.A. in economics from Yale University, where he was a Division I All New England Scholar Athlete lacrosse player.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDan holds Top Secret/SCI security clearances until their expiration.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDan is a regular contributor to the American Bar Association's Criminal Litigation Section's Practice Points publication\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eThe US v. Vascular Solutions Acquittal: Three Lessons for Targets of Off-Label Promotion Enforcement\u003c/em\u003e, Washington Legal Foundation Legal Backgrounder (2016)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eRecent Trends in Health Care Enforcement and Compliance\u003c/em\u003e, Inside the Minds: Health Care Law Enforcement and Compliance (Apastore 2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eThe Future of Off-Label Promotion Enforcement in the Wake of Caronia \u0026mdash; Toward a First Amendment Safe Harbor\u003c/em\u003e, The Sedona Conference Journal, Volume 14 (2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eOff-Label Promotion: The Criminalization of Scientific Exchange\u003c/em\u003e, Pharma Magazine (UK) (2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eFDA as Arbiter of Truth? The First Amendment, Caronia, and the Future of Off-Label Promotion Enforcement\u003c/em\u003e, ABA White Collar Crime (2013)\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eTenure Trap: Third Circuit Joins Sixth in Holding Tenure Buy-out Payments Subject to FICA Taxation in University of Pittsburgh v. United States\u003c/em\u003e, The Tax Lawyer, Volume 63 (2010)\u003c/li\u003e\n\u003c/ul\u003e","matters":["\u003cp\u003eRepresenting\u0026nbsp;\u003cem\u003epro bono\u003c/em\u003e\u0026nbsp;a former Army Ranger convicted by court martial of murder in Iraq, resulting in a full Presidential pardon.\u003c/p\u003e","\u003cp\u003eRepresenting an individual in connection with the Special Counsel investigation conducted by Robert Mueller.\u003c/p\u003e","\u003cp\u003eRepresenting a global pharmaceutical company in an industry-wide investigation regarding donations to charitable patient assistance foundations.\u003c/p\u003e","\u003cp\u003eSecured a declination of all criminal and civil liability for a global medical device manufacturer in an investigation involving off-label promotion and fraud issues\u003c/p\u003e","\u003cp\u003eRepresented Vascular Solutions, Inc., a publicly traded medical device manufacturer that was indicted on federal criminal charges relating to off-label promotion and acquitted by a jury of all charges after a four week trial in February 2016.\u003c/p\u003e","\u003cp\u003eRepresenting several individual witnesses and targets in connection with domestic and international investigations of foreign exchange (FX) trading, resulting in no charges.\u003c/p\u003e","\u003cp\u003eRepresented leading pharmaceutical manufacturers into off-label promotion issues by the Department of Justice and multiple U.S. Attorneys\u0026rsquo; Offices, the FDA, the Department of Health and Human Services Office of Inspector General, and various state Attorneys General, as well as parallel federal False Claims Act\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;litigation.\u003c/p\u003e","\u003cp\u003eRepresented current and former CEOs, high-level executives, and other individuals in FCPA investigations related to events throughout Latin America, the Middle East, China, Mexico, and Eastern Europe.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12360}]},"capability_group_id":2},"created_at":"2025-05-26T04:52:35.000Z","updated_at":"2025-05-26T04:52:35.000Z","searchable_text":"Sale{{ FIELD }}Representing pro bono a former Army Ranger convicted by court martial of murder in Iraq, resulting in a full Presidential pardon.{{ FIELD }}Representing an individual in connection with the Special Counsel investigation conducted by Robert Mueller.{{ FIELD }}Representing a global pharmaceutical company in an industry-wide investigation regarding donations to charitable patient assistance foundations.{{ FIELD }}Secured a declination of all criminal and civil liability for a global medical device manufacturer in an investigation involving off-label promotion and fraud issues{{ FIELD }}Represented Vascular Solutions, Inc., a publicly traded medical device manufacturer that was indicted on federal criminal charges relating to off-label promotion and acquitted by a jury of all charges after a four week trial in February 2016.{{ FIELD }}Representing several individual witnesses and targets in connection with domestic and international investigations of foreign exchange (FX) trading, resulting in no charges.{{ FIELD }}Represented leading pharmaceutical manufacturers into off-label promotion issues by the Department of Justice and multiple U.S. Attorneys’ Offices, the FDA, the Department of Health and Human Services Office of Inspector General, and various state Attorneys General, as well as parallel federal False Claims Act qui tam litigation.{{ FIELD }}Represented current and former CEOs, high-level executives, and other individuals in FCPA investigations related to events throughout Latin America, the Middle East, China, Mexico, and Eastern Europe.{{ FIELD }}Dan Sale defends clients in high-stakes government and Congressional investigations, enforcement proceedings, and parallel civil litigation.  Concentrating in complex criminal and civil litigation, Dan regularly represents life sciences companies, financial institutions, other highly-regulated companies, and their boards and senior executives in high-profile and sensitive investigations and litigation.  Dan has special experience in matters involving: life sciences criminal and civil investigations; Congressional investigations; the False Claims Act; financial crimes, the Foreign Corrupt Practices Act (FCPA);  antitrust and market manipulation matters; the securities laws; whistleblower cases; and transnational tax investigations. \nDan has special experience in cases involving allegations of off-label promotion and kickbacks in the life sciences industry and represented clients in the three largest Anti-Kickback Statute investigations ever resolved with DOJ.  Dan also has special experience in state attorney general investigations, and has personally negotiated quiet resolutions with all 50 state AG offices and the District of Columbia.  In addition, Dan has considerable experience defending clients in multi-jurisdictional investigations and litigation conducted cooperatively by United States, European, Middle Eastern, Asian and African authorities\nThe Special Matters \u0026amp; Government Investigations group has been twice recognized by Law 360 as the “White-Collar Group of the Year” and described as “the premier firm in this practice area” by the U.S. News \u0026amp; World Report/Best Lawyers’ “Best Law Firms” survey.\nDan began his legal career as a law clerk to the Honorable Richard D. Bennett of the United States District Court for the District of Maryland.  He received his J.D. from Georgetown University Law Center, where he was an Editorial Board Member of the Tax Lawyer law journal, and his B.A. in economics from Yale University, where he was a Division I All New England Scholar Athlete lacrosse player. \nDan holds Top Secret/SCI security clearances until their expiration.\nPublications\n\nDan is a regular contributor to the American Bar Association's Criminal Litigation Section's Practice Points publication\nThe US v. Vascular Solutions Acquittal: Three Lessons for Targets of Off-Label Promotion Enforcement, Washington Legal Foundation Legal Backgrounder (2016)\nRecent Trends in Health Care Enforcement and Compliance, Inside the Minds: Health Care Law Enforcement and Compliance (Apastore 2013)\nThe Future of Off-Label Promotion Enforcement in the Wake of Caronia — Toward a First Amendment Safe Harbor, The Sedona Conference Journal, Volume 14 (2013)\nOff-Label Promotion: The Criminalization of Scientific Exchange, Pharma Magazine (UK) (2013)\nFDA as Arbiter of Truth? The First Amendment, Caronia, and the Future of Off-Label Promotion Enforcement, ABA White Collar Crime (2013)\nTenure Trap: Third Circuit Joins Sixth in Holding Tenure Buy-out Payments Subject to FICA Taxation in University of Pittsburgh v. United States, The Tax Lawyer, Volume 63 (2010)\n Partner Yale University Yale Law School Georgetown University Georgetown University Law Center U.S. Court of Appeals for the Fourth Circuit U.S. District Court for the District of Maryland District of Columbia Maryland Law Clerk, Richard D. Bennett, U.S. District Court for the District of Maryland Representing pro bono a former Army Ranger convicted by court martial of murder in Iraq, resulting in a full Presidential pardon. Representing an individual in connection with the Special Counsel investigation conducted by Robert Mueller. Representing a global pharmaceutical company in an industry-wide investigation regarding donations to charitable patient assistance foundations. Secured a declination of all criminal and civil liability for a global medical device manufacturer in an investigation involving off-label promotion and fraud issues Represented Vascular Solutions, Inc., a publicly traded medical device manufacturer that was indicted on federal criminal charges relating to off-label promotion and acquitted by a jury of all charges after a four week trial in February 2016. Representing several individual witnesses and targets in connection with domestic and international investigations of foreign exchange (FX) trading, resulting in no charges. Represented leading pharmaceutical manufacturers into off-label promotion issues by the Department of Justice and multiple U.S. Attorneys’ Offices, the FDA, the Department of Health and Human Services Office of Inspector General, and various state Attorneys General, as well as parallel federal False Claims Act qui tam litigation. Represented current and former CEOs, high-level executives, and other individuals in FCPA investigations related to events throughout Latin America, the Middle East, China, Mexico, and Eastern Europe.","searchable_name":"Daniel C. Sale","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426539,"version":1,"owner_type":"Person","owner_id":4092,"payload":{"bio":"\u003cp\u003eKyle Sampson focuses on Food and Drug Administration regulatory, compliance and enforcement issues. As a partner in our FDA and Life Sciences practice, Kyle represents companies in the full range of regulatory and enforcement issues.\u003c/p\u003e\n\u003cp\u003e[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKyle advises food, drug, biologics, medical device, cosmetics and dietary supplement companies on FDA compliance, regulatory and enforcement matters. His practice also includes strategic advice and compliance counseling, enforcement, litigation and transactional matters.\u003c/p\u003e\n\u003cp\u003eKyle has engaged in extensive public service in every branch of the federal government. He served in the White House as Associate Counsel to the President; at the Department of Justice as a Special Assistant U.S. Attorney and as Counselor and Chief of Staff to two attorneys general; and in the U.S. Senate as Counsel to the Senate Judiciary Committee.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e","slug":"kyle-sampson","email":"ksampson@kslaw.com","phone":"+1 202 340 8202","matters":["\u003cp\u003eAssist \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device companies\u003c/strong\u003e in developing and implementing comprehensive regulatory and healthcare fraud and abuse compliance programs involving off-label promotion, anti-kickback violations, federal healthcare program reimbursement, and pricing and false claims actions.\u003c/p\u003e","\u003cp\u003eServe as counsel to \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical, biotechnology and medical device companies\u003c/strong\u003e in regulatory matters involving product development and commercialization.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device manufacturers\u003c/strong\u003e in responding to FDA enforcement actions, including Form FDA-483 observations and Warning Letters.\u003c/p\u003e","\u003cp\u003eServe as compliance counsel for \u003cstrong data-redactor-tag=\"strong\"\u003ea\u003c/strong\u003e \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical company\u003c/strong\u003e subject to consent decree resulting from allegation that company provided false scientific data to FDA in regulatory submissions.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003ea medical device manufacturer\u003c/strong\u003e in consent decree negotiations with FDA and Department of Justice.\u003c/p\u003e","\u003cp\u003eWith Monitor appointed by U.S. Attorney\u0026rsquo;s Office for the District of New Jersey under Deferred Prosecution Agreement (DPA), oversaw \u003cstrong data-redactor-tag=\"strong\"\u003eorthopedic device manufacturer\u003c/strong\u003e's compliance with federal Anti-Kickback Statute and other federal healthcare laws and its implementation of comprehensive compliance program.\u003c/p\u003e","\u003cp\u003eReview advertising and promotional materials and activities for prescription drugs, biologics and devices for \u003cstrong data-redactor-tag=\"strong\"\u003evarious clients.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eProvide advice to \u003cstrong data-redactor-tag=\"strong\"\u003emanufacturers\u003c/strong\u003e \u003cstrong data-redactor-tag=\"strong\"\u003eof controlled substances and listed chemicals\u003c/strong\u003e regarding compliance with the Controlled Substances Act and Drug Enforcement Administration regulations.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003emanufacturers of drug, medical device, human food, animal feed and consumer products\u003c/strong\u003e in negotiations with the FDA over recalls of manufacturers\u0026rsquo; products, including proper classification of recall, assessment of health hazard, and development and implementation of recall strategy.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003eforeign manufacturers and domestic importers\u003c/strong\u003e in responding to the FDA\u0026rsquo;s detention of imports and placement of firms on Import Alert, including negotiating firms\u0026rsquo; removal from Detention Without Physical Examination (DWPE).\u003c/p\u003e","\u003cp\u003eHelp \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device companies\u003c/strong\u003e respond to widespread counterfeiting of products and unlawful importation by Internet pharmacies and others in violation of the Federal Food, Drug, and Cosmetic Act and the Lanham Act.\u003c/p\u003e","\u003cul\u003e\n\u003cli\u003eProvided advice to two \u003cstrong data-redactor-tag=\"strong\"\u003eattorneys general\u003c/strong\u003e on legal and policy issues, coordinated Justice Department positions in criminal prosecutions and civil litigation, and formulated and implemented policy initiatives and legislative proposals.\u003c/li\u003e\n\u003c/ul\u003e","\u003cp\u003eAs Special Assistant U.S. Attorney, conducted \u003cstrong data-redactor-tag=\"strong\"\u003etrial and appellate litigation,\u003c/strong\u003e including arguing three cases in the U.S. Courts of Appeals for the Fourth and Ninth Circuits.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":103,"guid":"103.capabilities","index":0,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":4,"source":"smartTags"},{"id":112,"guid":"112.capabilities","index":5,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":6,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":7,"source":"smartTags"},{"id":133,"guid":"133.capabilities","index":8,"source":"capabilities"}],"is_active":true,"last_name":"Sampson","nick_name":"D.","clerkships":[{"name":"Law Clerk, Hon. Karen J. Williams, U.S. Court of Appeals for the Fourth Circuit","years_held":"1996-1997"}],"first_name":"D.","title_rank":9999,"updated_by":202,"law_schools":[{"id":2174,"meta":{"degree":"J.D.","honors":"with honors","is_law_school":1,"graduation_date":"1996-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"Kyle","name_suffix":"","recognitions":[{"title":"Attorney General’s Award for Outstanding Service to the Attorney General, the Department of Justice, and to America ","detail":"U.S. Department of Justice, 2005"}],"linked_in_url":"https://www.linkedin.com/in/kyle-sampson-4302348/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eKyle Sampson focuses on Food and Drug Administration regulatory, compliance and enforcement issues. As a partner in our FDA and Life Sciences practice, Kyle represents companies in the full range of regulatory and enforcement issues.\u003c/p\u003e\n\u003cp\u003e[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKyle advises food, drug, biologics, medical device, cosmetics and dietary supplement companies on FDA compliance, regulatory and enforcement matters. His practice also includes strategic advice and compliance counseling, enforcement, litigation and transactional matters.\u003c/p\u003e\n\u003cp\u003eKyle has engaged in extensive public service in every branch of the federal government. He served in the White House as Associate Counsel to the President; at the Department of Justice as a Special Assistant U.S. Attorney and as Counselor and Chief of Staff to two attorneys general; and in the U.S. Senate as Counsel to the Senate Judiciary Committee.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003eAssist \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device companies\u003c/strong\u003e in developing and implementing comprehensive regulatory and healthcare fraud and abuse compliance programs involving off-label promotion, anti-kickback violations, federal healthcare program reimbursement, and pricing and false claims actions.\u003c/p\u003e","\u003cp\u003eServe as counsel to \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical, biotechnology and medical device companies\u003c/strong\u003e in regulatory matters involving product development and commercialization.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device manufacturers\u003c/strong\u003e in responding to FDA enforcement actions, including Form FDA-483 observations and Warning Letters.\u003c/p\u003e","\u003cp\u003eServe as compliance counsel for \u003cstrong data-redactor-tag=\"strong\"\u003ea\u003c/strong\u003e \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical company\u003c/strong\u003e subject to consent decree resulting from allegation that company provided false scientific data to FDA in regulatory submissions.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003ea medical device manufacturer\u003c/strong\u003e in consent decree negotiations with FDA and Department of Justice.\u003c/p\u003e","\u003cp\u003eWith Monitor appointed by U.S. Attorney\u0026rsquo;s Office for the District of New Jersey under Deferred Prosecution Agreement (DPA), oversaw \u003cstrong data-redactor-tag=\"strong\"\u003eorthopedic device manufacturer\u003c/strong\u003e's compliance with federal Anti-Kickback Statute and other federal healthcare laws and its implementation of comprehensive compliance program.\u003c/p\u003e","\u003cp\u003eReview advertising and promotional materials and activities for prescription drugs, biologics and devices for \u003cstrong data-redactor-tag=\"strong\"\u003evarious clients.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eProvide advice to \u003cstrong data-redactor-tag=\"strong\"\u003emanufacturers\u003c/strong\u003e \u003cstrong data-redactor-tag=\"strong\"\u003eof controlled substances and listed chemicals\u003c/strong\u003e regarding compliance with the Controlled Substances Act and Drug Enforcement Administration regulations.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003emanufacturers of drug, medical device, human food, animal feed and consumer products\u003c/strong\u003e in negotiations with the FDA over recalls of manufacturers\u0026rsquo; products, including proper classification of recall, assessment of health hazard, and development and implementation of recall strategy.\u003c/p\u003e","\u003cp\u003eRepresent \u003cstrong data-redactor-tag=\"strong\"\u003eforeign manufacturers and domestic importers\u003c/strong\u003e in responding to the FDA\u0026rsquo;s detention of imports and placement of firms on Import Alert, including negotiating firms\u0026rsquo; removal from Detention Without Physical Examination (DWPE).\u003c/p\u003e","\u003cp\u003eHelp \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device companies\u003c/strong\u003e respond to widespread counterfeiting of products and unlawful importation by Internet pharmacies and others in violation of the Federal Food, Drug, and Cosmetic Act and the Lanham Act.\u003c/p\u003e","\u003cul\u003e\n\u003cli\u003eProvided advice to two \u003cstrong data-redactor-tag=\"strong\"\u003eattorneys general\u003c/strong\u003e on legal and policy issues, coordinated Justice Department positions in criminal prosecutions and civil litigation, and formulated and implemented policy initiatives and legislative proposals.\u003c/li\u003e\n\u003c/ul\u003e","\u003cp\u003eAs Special Assistant U.S. Attorney, conducted \u003cstrong data-redactor-tag=\"strong\"\u003etrial and appellate litigation,\u003c/strong\u003e including arguing three cases in the U.S. Courts of Appeals for the Fourth and Ninth Circuits.\u003c/p\u003e"],"recognitions":[{"title":"Attorney General’s Award for Outstanding Service to the Attorney General, the Department of Justice, and to America ","detail":"U.S. Department of Justice, 2005"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12357}]},"capability_group_id":2},"created_at":"2025-05-26T04:54:31.000Z","updated_at":"2025-05-26T04:54:31.000Z","searchable_text":"Sampson{{ FIELD }}{:title=\u0026gt;\"Attorney General’s Award for Outstanding Service to the Attorney General, the Department of Justice, and to America \", :detail=\u0026gt;\"U.S. Department of Justice, 2005\"}{{ FIELD }}Assist pharmaceutical and medical device companies in developing and implementing comprehensive regulatory and healthcare fraud and abuse compliance programs involving off-label promotion, anti-kickback violations, federal healthcare program reimbursement, and pricing and false claims actions.{{ FIELD }}Serve as counsel to pharmaceutical, biotechnology and medical device companies in regulatory matters involving product development and commercialization.{{ FIELD }}Represent pharmaceutical and medical device manufacturers in responding to FDA enforcement actions, including Form FDA-483 observations and Warning Letters.{{ FIELD }}Serve as compliance counsel for a pharmaceutical company subject to consent decree resulting from allegation that company provided false scientific data to FDA in regulatory submissions.{{ FIELD }}Represent a medical device manufacturer in consent decree negotiations with FDA and Department of Justice.{{ FIELD }}With Monitor appointed by U.S. Attorney’s Office for the District of New Jersey under Deferred Prosecution Agreement (DPA), oversaw orthopedic device manufacturer's compliance with federal Anti-Kickback Statute and other federal healthcare laws and its implementation of comprehensive compliance program.{{ FIELD }}Review advertising and promotional materials and activities for prescription drugs, biologics and devices for various clients.{{ FIELD }}Provide advice to manufacturers of controlled substances and listed chemicals regarding compliance with the Controlled Substances Act and Drug Enforcement Administration regulations.{{ FIELD }}Represent manufacturers of drug, medical device, human food, animal feed and consumer products in negotiations with the FDA over recalls of manufacturers’ products, including proper classification of recall, assessment of health hazard, and development and implementation of recall strategy.{{ FIELD }}Represent foreign manufacturers and domestic importers in responding to the FDA’s detention of imports and placement of firms on Import Alert, including negotiating firms’ removal from Detention Without Physical Examination (DWPE).{{ FIELD }}Help pharmaceutical and medical device companies respond to widespread counterfeiting of products and unlawful importation by Internet pharmacies and others in violation of the Federal Food, Drug, and Cosmetic Act and the Lanham Act.{{ FIELD }}\nProvided advice to two attorneys general on legal and policy issues, coordinated Justice Department positions in criminal prosecutions and civil litigation, and formulated and implemented policy initiatives and legislative proposals.\n{{ FIELD }}As Special Assistant U.S. Attorney, conducted trial and appellate litigation, including arguing three cases in the U.S. Courts of Appeals for the Fourth and Ninth Circuits.{{ FIELD }}Kyle Sampson focuses on Food and Drug Administration regulatory, compliance and enforcement issues. As a partner in our FDA and Life Sciences practice, Kyle represents companies in the full range of regulatory and enforcement issues.\n\nKyle advises food, drug, biologics, medical device, cosmetics and dietary supplement companies on FDA compliance, regulatory and enforcement matters. His practice also includes strategic advice and compliance counseling, enforcement, litigation and transactional matters.\nKyle has engaged in extensive public service in every branch of the federal government. He served in the White House as Associate Counsel to the President; at the Department of Justice as a Special Assistant U.S. Attorney and as Counselor and Chief of Staff to two attorneys general; and in the U.S. Senate as Counsel to the Senate Judiciary Committee.\n \n  Partner Attorney General’s Award for Outstanding Service to the Attorney General, the Department of Justice, and to America  U.S. Department of Justice, 2005 Brigham Young University J. Reuben Clark Law School University of Chicago University of Chicago Law School U.S. Court of Appeals for the Fourth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. Court of Appeals for the D.C. Circuit U.S. District Court for the District of Utah District of Columbia Utah Law Clerk, Hon. Karen J. Williams, U.S. Court of Appeals for the Fourth Circuit Assist pharmaceutical and medical device companies in developing and implementing comprehensive regulatory and healthcare fraud and abuse compliance programs involving off-label promotion, anti-kickback violations, federal healthcare program reimbursement, and pricing and false claims actions. Serve as counsel to pharmaceutical, biotechnology and medical device companies in regulatory matters involving product development and commercialization. Represent pharmaceutical and medical device manufacturers in responding to FDA enforcement actions, including Form FDA-483 observations and Warning Letters. Serve as compliance counsel for a pharmaceutical company subject to consent decree resulting from allegation that company provided false scientific data to FDA in regulatory submissions. Represent a medical device manufacturer in consent decree negotiations with FDA and Department of Justice. With Monitor appointed by U.S. Attorney’s Office for the District of New Jersey under Deferred Prosecution Agreement (DPA), oversaw orthopedic device manufacturer's compliance with federal Anti-Kickback Statute and other federal healthcare laws and its implementation of comprehensive compliance program. Review advertising and promotional materials and activities for prescription drugs, biologics and devices for various clients. Provide advice to manufacturers of controlled substances and listed chemicals regarding compliance with the Controlled Substances Act and Drug Enforcement Administration regulations. Represent manufacturers of drug, medical device, human food, animal feed and consumer products in negotiations with the FDA over recalls of manufacturers’ products, including proper classification of recall, assessment of health hazard, and development and implementation of recall strategy. Represent foreign manufacturers and domestic importers in responding to the FDA’s detention of imports and placement of firms on Import Alert, including negotiating firms’ removal from Detention Without Physical Examination (DWPE). Help pharmaceutical and medical device companies respond to widespread counterfeiting of products and unlawful importation by Internet pharmacies and others in violation of the Federal Food, Drug, and Cosmetic Act and the Lanham Act. \nProvided advice to two attorneys general on legal and policy issues, coordinated Justice Department positions in criminal prosecutions and civil litigation, and formulated and implemented policy initiatives and legislative proposals.\n As Special Assistant U.S. Attorney, conducted trial and appellate litigation, including arguing three cases in the U.S. Courts of Appeals for the Fourth and Ninth Circuits.","searchable_name":"D. Kyle Sampson","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426468,"version":1,"owner_type":"Person","owner_id":3787,"payload":{"bio":"\u003cp\u003eWilliam (Bill) Sauers represents clients on high-stakes environmental matters, investigations, and technical matters.\u0026nbsp; As a partner in our Environmental, Health and Safety practice, Bill represents clients in a wide range of environmental enforcement, litigation, and compliance matters.\u0026nbsp; He also represents clients in complex litigation and counseling matters regarding trade secret, trademark, patent and copyright matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eHis recent environmental matters include representation of several\u0026nbsp;auto manufacturers in enforcement matters related to compliance with the Clean Air Act and related regulations before the Environmental Protection Agency (EPA), the California Air Resources Board (CARB), the Department of Justice (DOJ), and other federal and state agencies.\u003c/p\u003e\n\u003cp\u003eIn addition to extensive IP litigation and trial experience, Bill also advises clients on developing and protecting IP portfolios, including the identification, protection, licensing and enforcement of trademarks, copyrights and trade secrets.\u003c/p\u003e","slug":"william-sauers","email":"wsauers@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":252}]},"expertise":[{"id":106,"guid":"106.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":13,"guid":"13.capabilities","index":3,"source":"capabilities"},{"id":763,"guid":"763.smart_tags","index":4,"source":"smartTags"},{"id":16,"guid":"16.capabilities","index":5,"source":"capabilities"},{"id":105,"guid":"105.capabilities","index":6,"source":"capabilities"},{"id":71,"guid":"71.capabilities","index":7,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":8,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":9,"source":"capabilities"}],"is_active":true,"last_name":"Sauers","nick_name":"Bill","clerkships":[],"first_name":"William","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"J.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eWilliam (Bill) Sauers represents clients on high-stakes environmental matters, investigations, and technical matters.\u0026nbsp; As a partner in our Environmental, Health and Safety practice, Bill represents clients in a wide range of environmental enforcement, litigation, and compliance matters.\u0026nbsp; He also represents clients in complex litigation and counseling matters regarding trade secret, trademark, patent and copyright matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eHis recent environmental matters include representation of several\u0026nbsp;auto manufacturers in enforcement matters related to compliance with the Clean Air Act and related regulations before the Environmental Protection Agency (EPA), the California Air Resources Board (CARB), the Department of Justice (DOJ), and other federal and state agencies.\u003c/p\u003e\n\u003cp\u003eIn addition to extensive IP litigation and trial experience, Bill also advises clients on developing and protecting IP portfolios, including the identification, protection, licensing and enforcement of trademarks, copyrights and trade secrets.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6104}]},"capability_group_id":2},"created_at":"2025-05-26T04:53:31.000Z","updated_at":"2025-05-26T04:53:31.000Z","searchable_text":"Sauers{{ FIELD }}William (Bill) Sauers represents clients on high-stakes environmental matters, investigations, and technical matters.  As a partner in our Environmental, Health and Safety practice, Bill represents clients in a wide range of environmental enforcement, litigation, and compliance matters.  He also represents clients in complex litigation and counseling matters regarding trade secret, trademark, patent and copyright matters.\nHis recent environmental matters include representation of several auto manufacturers in enforcement matters related to compliance with the Clean Air Act and related regulations before the Environmental Protection Agency (EPA), the California Air Resources Board (CARB), the Department of Justice (DOJ), and other federal and state agencies.\nIn addition to extensive IP litigation and trial experience, Bill also advises clients on developing and protecting IP portfolios, including the identification, protection, licensing and enforcement of trademarks, copyrights and trade secrets. William J. Sauers Partner Supreme Court of the United States District of Columbia Pennsylvania","searchable_name":"William J. Sauers (Bill)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":442389,"version":1,"owner_type":"Person","owner_id":1036,"payload":{"bio":"\u003cp\u003eChristine Savage leads our firm's practice in sanctions law, export controls, and national security investigations of inbound U.S. investment before the Committee on Foreign Investment in the U.S. (\"CFIUS\").[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eChristine has over 25\u0026nbsp;years of experience helping clients handle their\u0026nbsp;international trade regulatory, compliance, and investigation needs.\u0026nbsp; She advises clients in a broad range of industries, including aerospace and defense, energy, FinTech and financial services, semiconductors and information technology, and biotechnology, on issues involving sanctions and export control laws.\u0026nbsp; She also assists clients in evaluating foreign investment transactions in sensitive U.S. industries and technologies, including helping them navigate proceedings before CFIUS. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eChristine looks for practical ways to help solve our clients' concerns, including defending clients in enforcement proceedings\u0026nbsp; and inquiries before the Office of Foreign Assets Control, Bureau of Industry and Security, and Directorate of Defense Trade Controls; assisting clients with internal investigations and compliance programs; and analyzing and structuring complex regulatory and licensing solutions.\u0026nbsp; She also represents\u0026nbsp;clients' interests before the Executive Branch and Congress on the impact of trade and national security regulations on their businesses, including advocating for\u0026nbsp;legislative and regulatory solutions to help advance their trade and investment goals.\u003c/p\u003e\n\u003cp\u003ePreviously, Christine served as an advisor in the International Trade Administration at the U.S. Department of Commerce.\u0026nbsp; In that\u0026nbsp;role, she acted as counsel to the government in\u0026nbsp;trade remedy proceedings and litigation involving numerous countries. She also engaged with foreign government officials and industry experts as part of a U.S. government team involved in White House trade initiatives.\u003c/p\u003e\n\u003cp\u003eChristine was recommended by \u003cem\u003eLegal 500 U.S.\u003c/em\u003e in the International Trade category. She is recognized by \u003cem\u003eChambers Global\u003c/em\u003e and \u003cem\u003eChambers U.S.A.\u003c/em\u003e in the International Trade: Export Controls \u0026amp; Economic Sanctions category.\u003c/p\u003e","slug":"christine-savage","email":"csavage@kslaw.com","phone":null,"matters":["\u003cp\u003eAssisted\u0026nbsp;\u003cstrong\u003eenergy, infrastructure, defense, and biotechnology companies\u003c/strong\u003e\u0026nbsp;in evaluating their export controls and compliance procedures for purposes of positioning their investment strategies for clearance by CFIUS.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eseveral U.S. and non-U.S. aerospace and defense companies\u003c/strong\u003e\u0026nbsp;in conducting internal investigations of export control and economic sanctions laws and preparing voluntary disclosures before the Bureau of Industry and Security, Directorate of Defense Trade Controls, and the Office of Foreign Assets Control.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ecompanies in the FinTech industry\u003c/strong\u003e\u0026nbsp;with respect to economic sanctions compliance before OFAC, including responding to government subpoenas, penalty actions, conducting internal investigations, helping to design effective compliance programs, and addressing novel licensing issues.\u003c/p\u003e","\u003cp\u003eAssisted in obtaining clearance by CFIUS for\u0026nbsp;\u003cstrong\u003ecompanies in sensitive sectors, including defense, critical technology, and critical infrastructure industries\u0026nbsp;\u003c/strong\u003eof foreign investment, including addressing issues related to Foreign Ownership, Control and Influence, as well as assisting the companies in negotiating mitigation agreements with the U.S. government.\u003c/p\u003e","\u003cp\u003eAssisted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003enumerous clients in the pharmaceutical, medical device and agricultural industries\u003c/strong\u003e\u0026nbsp;in obtaining licenses from OFAC for the sale of products in sanctioned countries, including Cuba, Iran and Syria, as well as assisting companies in designing compliance procedures to use existing U.S. government general licenses and license exceptions in a lawful manner.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":25,"guid":"25.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":1327,"guid":"1327.smart_tags","index":2,"source":"smartTags"},{"id":128,"guid":"128.capabilities","index":3,"source":"capabilities"},{"id":1330,"guid":"1330.smart_tags","index":4,"source":"smartTags"},{"id":23,"guid":"23.capabilities","index":5,"source":"capabilities"},{"id":1188,"guid":"1188.smart_tags","index":6,"source":"smartTags"},{"id":1142,"guid":"1142.smart_tags","index":7,"source":"smartTags"},{"id":107,"guid":"107.capabilities","index":8,"source":"capabilities"},{"id":699,"guid":"699.smart_tags","index":9,"source":"smartTags"},{"id":765,"guid":"765.smart_tags","index":10,"source":"smartTags"},{"id":579,"guid":"579.smart_tags","index":11,"source":"smartTags"},{"id":106,"guid":"106.capabilities","index":12,"source":"capabilities"},{"id":133,"guid":"133.capabilities","index":13,"source":"capabilities"},{"id":1233,"guid":"1233.smart_tags","index":14,"source":"smartTags"},{"id":103,"guid":"103.capabilities","index":15,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":16,"source":"capabilities"}],"is_active":true,"last_name":"Savage","nick_name":"Christine","clerkships":[],"first_name":"Christine","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":"E.","name_suffix":"","recognitions":[{"title":"Leading Partner, International Trade and National Security: Customs, Export Controls and Economic Sanctions","detail":"Legal 500 USA (2025)"},{"title":"\"Christine has a deep understanding of this area of law and gets all aspects.\"","detail":"Chambers USA, Nationwide (2025)"},{"title":"“She has a phenomenal grasp of the law and her guidance reliably balances the practicalities of our business with...”","detail":"Chambers USA (2023)"},{"title":"“Christine explores legal options with clients to meet business needs and legal obligations.”","detail":"Chambers USA (2023)"},{"title":"“She is able to give practical advice which is solution-orientated.”","detail":"Chambers USA (2023)"},{"title":"“Christine Savage is an expert's expert. She is thorough, business-minded and risk-focused in her advice.”","detail":" Chambers USA (2022)"},{"title":"“She is extremely effective and extraordinarily knowledgeable about export controls issues.”","detail":"Chambers Global (2022)"},{"title":"Top Ranked Lawyer, International Trade: Export Controls \u0026 Economic Sanctions ","detail":"Chambers Global, USA (2012, 2018-2025)"},{"title":"Top Ranked Lawyer, International Trade: Export Controls \u0026 Economic Sanctions","detail":"Chambers USA, Nationwide (2010-2011, 2017-2025)"},{"title":"“Exceptionally well versed in various trade regulations and has provided very insightful counsel...”","detail":"Chambers USA (2018)"},{"title":"Top Rated International Lawyer","detail":"Super Lawyers, Washington, D.C."},{"title":"Recognized Practitioner","detail":"Legal 500 US"}],"linked_in_url":"https://www.linkedin.com/in/christinesavage/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eChristine Savage leads our firm's practice in sanctions law, export controls, and national security investigations of inbound U.S. investment before the Committee on Foreign Investment in the U.S. (\"CFIUS\").[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eChristine has over 25\u0026nbsp;years of experience helping clients handle their\u0026nbsp;international trade regulatory, compliance, and investigation needs.\u0026nbsp; She advises clients in a broad range of industries, including aerospace and defense, energy, FinTech and financial services, semiconductors and information technology, and biotechnology, on issues involving sanctions and export control laws.\u0026nbsp; She also assists clients in evaluating foreign investment transactions in sensitive U.S. industries and technologies, including helping them navigate proceedings before CFIUS. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eChristine looks for practical ways to help solve our clients' concerns, including defending clients in enforcement proceedings\u0026nbsp; and inquiries before the Office of Foreign Assets Control, Bureau of Industry and Security, and Directorate of Defense Trade Controls; assisting clients with internal investigations and compliance programs; and analyzing and structuring complex regulatory and licensing solutions.\u0026nbsp; She also represents\u0026nbsp;clients' interests before the Executive Branch and Congress on the impact of trade and national security regulations on their businesses, including advocating for\u0026nbsp;legislative and regulatory solutions to help advance their trade and investment goals.\u003c/p\u003e\n\u003cp\u003ePreviously, Christine served as an advisor in the International Trade Administration at the U.S. Department of Commerce.\u0026nbsp; In that\u0026nbsp;role, she acted as counsel to the government in\u0026nbsp;trade remedy proceedings and litigation involving numerous countries. She also engaged with foreign government officials and industry experts as part of a U.S. government team involved in White House trade initiatives.\u003c/p\u003e\n\u003cp\u003eChristine was recommended by \u003cem\u003eLegal 500 U.S.\u003c/em\u003e in the International Trade category. She is recognized by \u003cem\u003eChambers Global\u003c/em\u003e and \u003cem\u003eChambers U.S.A.\u003c/em\u003e in the International Trade: Export Controls \u0026amp; Economic Sanctions category.\u003c/p\u003e","matters":["\u003cp\u003eAssisted\u0026nbsp;\u003cstrong\u003eenergy, infrastructure, defense, and biotechnology companies\u003c/strong\u003e\u0026nbsp;in evaluating their export controls and compliance procedures for purposes of positioning their investment strategies for clearance by CFIUS.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eseveral U.S. and non-U.S. aerospace and defense companies\u003c/strong\u003e\u0026nbsp;in conducting internal investigations of export control and economic sanctions laws and preparing voluntary disclosures before the Bureau of Industry and Security, Directorate of Defense Trade Controls, and the Office of Foreign Assets Control.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ecompanies in the FinTech industry\u003c/strong\u003e\u0026nbsp;with respect to economic sanctions compliance before OFAC, including responding to government subpoenas, penalty actions, conducting internal investigations, helping to design effective compliance programs, and addressing novel licensing issues.\u003c/p\u003e","\u003cp\u003eAssisted in obtaining clearance by CFIUS for\u0026nbsp;\u003cstrong\u003ecompanies in sensitive sectors, including defense, critical technology, and critical infrastructure industries\u0026nbsp;\u003c/strong\u003eof foreign investment, including addressing issues related to Foreign Ownership, Control and Influence, as well as assisting the companies in negotiating mitigation agreements with the U.S. government.\u003c/p\u003e","\u003cp\u003eAssisted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003enumerous clients in the pharmaceutical, medical device and agricultural industries\u003c/strong\u003e\u0026nbsp;in obtaining licenses from OFAC for the sale of products in sanctioned countries, including Cuba, Iran and Syria, as well as assisting companies in designing compliance procedures to use existing U.S. government general licenses and license exceptions in a lawful manner.\u003c/p\u003e"],"recognitions":[{"title":"Leading Partner, International Trade and National Security: Customs, Export Controls and Economic Sanctions","detail":"Legal 500 USA (2025)"},{"title":"\"Christine has a deep understanding of this area of law and gets all aspects.\"","detail":"Chambers USA, Nationwide (2025)"},{"title":"“She has a phenomenal grasp of the law and her guidance reliably balances the practicalities of our business with...”","detail":"Chambers USA (2023)"},{"title":"“Christine explores legal options with clients to meet business needs and legal obligations.”","detail":"Chambers USA (2023)"},{"title":"“She is able to give practical advice which is solution-orientated.”","detail":"Chambers USA (2023)"},{"title":"“Christine Savage is an expert's expert. She is thorough, business-minded and risk-focused in her advice.”","detail":" Chambers USA (2022)"},{"title":"“She is extremely effective and extraordinarily knowledgeable about export controls issues.”","detail":"Chambers Global (2022)"},{"title":"Top Ranked Lawyer, International Trade: Export Controls \u0026 Economic Sanctions ","detail":"Chambers Global, USA (2012, 2018-2025)"},{"title":"Top Ranked Lawyer, International Trade: Export Controls \u0026 Economic Sanctions","detail":"Chambers USA, Nationwide (2010-2011, 2017-2025)"},{"title":"“Exceptionally well versed in various trade regulations and has provided very insightful counsel...”","detail":"Chambers USA (2018)"},{"title":"Top Rated International Lawyer","detail":"Super Lawyers, Washington, D.C."},{"title":"Recognized Practitioner","detail":"Legal 500 US"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":1165},{"id":1165}]},"capability_group_id":2},"created_at":"2025-11-05T05:04:06.000Z","updated_at":"2025-11-05T05:04:06.000Z","searchable_text":"Savage{{ FIELD }}{:title=\u0026gt;\"Leading Partner, International Trade and National Security: Customs, Export Controls and Economic Sanctions\", :detail=\u0026gt;\"Legal 500 USA (2025)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Christine has a deep understanding of this area of law and gets all aspects.\\\"\", :detail=\u0026gt;\"Chambers USA, Nationwide (2025)\"}{{ FIELD }}{:title=\u0026gt;\"“She has a phenomenal grasp of the law and her guidance reliably balances the practicalities of our business with...”\", :detail=\u0026gt;\"Chambers USA (2023)\"}{{ FIELD }}{:title=\u0026gt;\"“Christine explores legal options with clients to meet business needs and legal obligations.”\", :detail=\u0026gt;\"Chambers USA (2023)\"}{{ FIELD }}{:title=\u0026gt;\"“She is able to give practical advice which is solution-orientated.”\", :detail=\u0026gt;\"Chambers USA (2023)\"}{{ FIELD }}{:title=\u0026gt;\"“Christine Savage is an expert's expert. She is thorough, business-minded and risk-focused in her advice.”\", :detail=\u0026gt;\" Chambers USA (2022)\"}{{ FIELD }}{:title=\u0026gt;\"“She is extremely effective and extraordinarily knowledgeable about export controls issues.”\", :detail=\u0026gt;\"Chambers Global (2022)\"}{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, International Trade: Export Controls \u0026amp; Economic Sanctions \", :detail=\u0026gt;\"Chambers Global, USA (2012, 2018-2025)\"}{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, International Trade: Export Controls \u0026amp; Economic Sanctions\", :detail=\u0026gt;\"Chambers USA, Nationwide (2010-2011, 2017-2025)\"}{{ FIELD }}{:title=\u0026gt;\"“Exceptionally well versed in various trade regulations and has provided very insightful counsel...”\", :detail=\u0026gt;\"Chambers USA (2018)\"}{{ FIELD }}{:title=\u0026gt;\"Top Rated International Lawyer\", :detail=\u0026gt;\"Super Lawyers, Washington, D.C.\"}{{ FIELD }}{:title=\u0026gt;\"Recognized Practitioner\", :detail=\u0026gt;\"Legal 500 US\"}{{ FIELD }}Assisted energy, infrastructure, defense, and biotechnology companies in evaluating their export controls and compliance procedures for purposes of positioning their investment strategies for clearance by CFIUS.{{ FIELD }}Represented several U.S. and non-U.S. aerospace and defense companies in conducting internal investigations of export control and economic sanctions laws and preparing voluntary disclosures before the Bureau of Industry and Security, Directorate of Defense Trade Controls, and the Office of Foreign Assets Control.{{ FIELD }}Representing companies in the FinTech industry with respect to economic sanctions compliance before OFAC, including responding to government subpoenas, penalty actions, conducting internal investigations, helping to design effective compliance programs, and addressing novel licensing issues.{{ FIELD }}Assisted in obtaining clearance by CFIUS for companies in sensitive sectors, including defense, critical technology, and critical infrastructure industries of foreign investment, including addressing issues related to Foreign Ownership, Control and Influence, as well as assisting the companies in negotiating mitigation agreements with the U.S. government.{{ FIELD }}Assisted numerous clients in the pharmaceutical, medical device and agricultural industries in obtaining licenses from OFAC for the sale of products in sanctioned countries, including Cuba, Iran and Syria, as well as assisting companies in designing compliance procedures to use existing U.S. government general licenses and license exceptions in a lawful manner.{{ FIELD }}Christine Savage leads our firm's practice in sanctions law, export controls, and national security investigations of inbound U.S. investment before the Committee on Foreign Investment in the U.S. (\"CFIUS\").\nChristine has over 25 years of experience helping clients handle their international trade regulatory, compliance, and investigation needs.  She advises clients in a broad range of industries, including aerospace and defense, energy, FinTech and financial services, semiconductors and information technology, and biotechnology, on issues involving sanctions and export control laws.  She also assists clients in evaluating foreign investment transactions in sensitive U.S. industries and technologies, including helping them navigate proceedings before CFIUS.  \nChristine looks for practical ways to help solve our clients' concerns, including defending clients in enforcement proceedings  and inquiries before the Office of Foreign Assets Control, Bureau of Industry and Security, and Directorate of Defense Trade Controls; assisting clients with internal investigations and compliance programs; and analyzing and structuring complex regulatory and licensing solutions.  She also represents clients' interests before the Executive Branch and Congress on the impact of trade and national security regulations on their businesses, including advocating for legislative and regulatory solutions to help advance their trade and investment goals.\nPreviously, Christine served as an advisor in the International Trade Administration at the U.S. Department of Commerce.  In that role, she acted as counsel to the government in trade remedy proceedings and litigation involving numerous countries. She also engaged with foreign government officials and industry experts as part of a U.S. government team involved in White House trade initiatives.\nChristine was recommended by Legal 500 U.S. in the International Trade category. She is recognized by Chambers Global and Chambers U.S.A. in the International Trade: Export Controls \u0026amp; Economic Sanctions category. Partner Leading Partner, International Trade and National Security: Customs, Export Controls and Economic Sanctions Legal 500 USA (2025) \"Christine has a deep understanding of this area of law and gets all aspects.\" Chambers USA, Nationwide (2025) “She has a phenomenal grasp of the law and her guidance reliably balances the practicalities of our business with...” Chambers USA (2023) “Christine explores legal options with clients to meet business needs and legal obligations.” Chambers USA (2023) “She is able to give practical advice which is solution-orientated.” Chambers USA (2023) “Christine Savage is an expert's expert. She is thorough, business-minded and risk-focused in her advice.”  Chambers USA (2022) “She is extremely effective and extraordinarily knowledgeable about export controls issues.” Chambers Global (2022) Top Ranked Lawyer, International Trade: Export Controls \u0026amp; Economic Sanctions  Chambers Global, USA (2012, 2018-2025) Top Ranked Lawyer, International Trade: Export Controls \u0026amp; Economic Sanctions Chambers USA, Nationwide (2010-2011, 2017-2025) “Exceptionally well versed in various trade regulations and has provided very insightful counsel...” Chambers USA (2018) Top Rated International Lawyer Super Lawyers, Washington, D.C. Recognized Practitioner Legal 500 US University of Michigan University of Michigan Law School Columbus School of Law, Catholic University of America Columbus School of Law, Catholic University of America U.S. Court of Appeals for the Federal Circuit U.S. Court of International Trade District of Columbia New York The District of Columbia Bar United States Court of Appeals for the Federal Circuit Court of International Trade American Bar Association, International Trade Section, Export Committee Assisted energy, infrastructure, defense, and biotechnology companies in evaluating their export controls and compliance procedures for purposes of positioning their investment strategies for clearance by CFIUS. Represented several U.S. and non-U.S. aerospace and defense companies in conducting internal investigations of export control and economic sanctions laws and preparing voluntary disclosures before the Bureau of Industry and Security, Directorate of Defense Trade Controls, and the Office of Foreign Assets Control. Representing companies in the FinTech industry with respect to economic sanctions compliance before OFAC, including responding to government subpoenas, penalty actions, conducting internal investigations, helping to design effective compliance programs, and addressing novel licensing issues. Assisted in obtaining clearance by CFIUS for companies in sensitive sectors, including defense, critical technology, and critical infrastructure industries of foreign investment, including addressing issues related to Foreign Ownership, Control and Influence, as well as assisting the companies in negotiating mitigation agreements with the U.S. government. Assisted numerous clients in the pharmaceutical, medical device and agricultural industries in obtaining licenses from OFAC for the sale of products in sanctioned countries, including Cuba, Iran and Syria, as well as assisting companies in designing compliance procedures to use existing U.S. government general licenses and license exceptions in a lawful manner.","searchable_name":"Christine E. Savage","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":442855,"version":1,"owner_type":"Person","owner_id":6047,"payload":{"bio":"\u003cp\u003eA former two-time U.S. Attorney for the Eastern District of California, a 34-county district headquartered in Sacramento\u0026nbsp;with an area that stretches from the Oregon border to Bakersfield, Greg Scott is an experienced trial lawyer who represents major companies facing government investigations and litigation, with a focus in the healthcare, retail, and construction industries. He has extensive knowledge on matters involving consumer protection, construction accidents, the Foreign Corrupt Practices Act (FCPA) and the False Claims Act (FCA).\u0026nbsp; The combination of his vast experience as a prosecutor and conducting internal investigations as a defense attorney consistently leads to great results for his clients.\u0026nbsp;\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGreg represents corporations under criminal and/or civil\u0026nbsp;investigation by Federal, state, and local prosecutors' offices.\u0026nbsp; He has extensive experience conducing internal investigations for companies under scrutiny in a wide-range of subject matters, including health care, consumer protection, the False Claims Act, and Foreign Corrupt Practices Act.\u0026nbsp; Greg has been on the opposite side of the table in investigations brought by multiple Federal agencies, the California Attorney General, and several California District Attorneys.\u0026nbsp;\u0026nbsp;\u0026nbsp;The combination of his experience as a prosecutor and as a defense attorney and his stature among prosecutors in California has led to great results for his clients.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGreg started his legal career as a deputy district attorney in Contra Costa County. CA where he tried approximately 100 jury trials to verdict and then became the\u0026nbsp;twice-elected District Attorney of Shasta County, CA. He also served as an Adjunct Professor of National Security Law at the McGeorge School of Law following his first term as U.S. Attorney for the E.D. of California. Between his two terms as U.S. Attorney, Greg was the vice chair of the white-collar defense and corporate investigations practice at an AmLaw 50 firm.\u0026nbsp; \u0026nbsp;He retired as a lieutenant colonel from the U.S. Army Reserve after 23 years of service as an infantry officer.\u0026nbsp;\u003c/p\u003e","slug":"greg-scott","email":"mscott@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":1,"source":"capabilities"},{"id":4,"guid":"4.capabilities","index":2,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":6,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":7,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":8,"source":"smartTags"},{"id":1199,"guid":"1199.smart_tags","index":9,"source":"smartTags"}],"is_active":true,"last_name":"Scott","nick_name":"Greg","clerkships":[],"first_name":"McGregor","title_rank":9999,"updated_by":32,"law_schools":[{"id":2158,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1989-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Named Lawyer of the Year for Criminal Defense: White-Collar in Sacramento","detail":"Best Lawyers® in America (2023)"},{"title":"Recognized for Criminal Defense: White-Collar","detail":"Best Lawyers in America (2013-2023)"}],"linked_in_url":"https://www.linkedin.com/in/mcgregor-scott-9527ba21/","seodescription":null,"primary_title_id":155,"translated_fields":{"en":{"bio":"\u003cp\u003eA former two-time U.S. Attorney for the Eastern District of California, a 34-county district headquartered in Sacramento\u0026nbsp;with an area that stretches from the Oregon border to Bakersfield, Greg Scott is an experienced trial lawyer who represents major companies facing government investigations and litigation, with a focus in the healthcare, retail, and construction industries. He has extensive knowledge on matters involving consumer protection, construction accidents, the Foreign Corrupt Practices Act (FCPA) and the False Claims Act (FCA).\u0026nbsp; The combination of his vast experience as a prosecutor and conducting internal investigations as a defense attorney consistently leads to great results for his clients.\u0026nbsp;\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGreg represents corporations under criminal and/or civil\u0026nbsp;investigation by Federal, state, and local prosecutors' offices.\u0026nbsp; He has extensive experience conducing internal investigations for companies under scrutiny in a wide-range of subject matters, including health care, consumer protection, the False Claims Act, and Foreign Corrupt Practices Act.\u0026nbsp; Greg has been on the opposite side of the table in investigations brought by multiple Federal agencies, the California Attorney General, and several California District Attorneys.\u0026nbsp;\u0026nbsp;\u0026nbsp;The combination of his experience as a prosecutor and as a defense attorney and his stature among prosecutors in California has led to great results for his clients.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGreg started his legal career as a deputy district attorney in Contra Costa County. CA where he tried approximately 100 jury trials to verdict and then became the\u0026nbsp;twice-elected District Attorney of Shasta County, CA. He also served as an Adjunct Professor of National Security Law at the McGeorge School of Law following his first term as U.S. Attorney for the E.D. of California. Between his two terms as U.S. Attorney, Greg was the vice chair of the white-collar defense and corporate investigations practice at an AmLaw 50 firm.\u0026nbsp; \u0026nbsp;He retired as a lieutenant colonel from the U.S. Army Reserve after 23 years of service as an infantry officer.\u0026nbsp;\u003c/p\u003e","recognitions":[{"title":"Named Lawyer of the Year for Criminal Defense: White-Collar in Sacramento","detail":"Best Lawyers® in America (2023)"},{"title":"Recognized for Criminal Defense: White-Collar","detail":"Best Lawyers in America (2013-2023)"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":8858}]},"capability_group_id":2},"created_at":"2025-11-13T04:58:49.000Z","updated_at":"2025-11-13T04:58:49.000Z","searchable_text":"Scott{{ FIELD }}{:title=\u0026gt;\"Named Lawyer of the Year for Criminal Defense: White-Collar in Sacramento\", :detail=\u0026gt;\"Best Lawyers® in America (2023)\"}{{ FIELD }}{:title=\u0026gt;\"Recognized for Criminal Defense: White-Collar\", :detail=\u0026gt;\"Best Lawyers in America (2013-2023)\"}{{ FIELD }}A former two-time U.S. Attorney for the Eastern District of California, a 34-county district headquartered in Sacramento with an area that stretches from the Oregon border to Bakersfield, Greg Scott is an experienced trial lawyer who represents major companies facing government investigations and litigation, with a focus in the healthcare, retail, and construction industries. He has extensive knowledge on matters involving consumer protection, construction accidents, the Foreign Corrupt Practices Act (FCPA) and the False Claims Act (FCA).  The combination of his vast experience as a prosecutor and conducting internal investigations as a defense attorney consistently leads to great results for his clients.  \nGreg represents corporations under criminal and/or civil investigation by Federal, state, and local prosecutors' offices.  He has extensive experience conducing internal investigations for companies under scrutiny in a wide-range of subject matters, including health care, consumer protection, the False Claims Act, and Foreign Corrupt Practices Act.  Greg has been on the opposite side of the table in investigations brought by multiple Federal agencies, the California Attorney General, and several California District Attorneys.   The combination of his experience as a prosecutor and as a defense attorney and his stature among prosecutors in California has led to great results for his clients.  \nGreg started his legal career as a deputy district attorney in Contra Costa County. CA where he tried approximately 100 jury trials to verdict and then became the twice-elected District Attorney of Shasta County, CA. He also served as an Adjunct Professor of National Security Law at the McGeorge School of Law following his first term as U.S. Attorney for the E.D. of California. Between his two terms as U.S. Attorney, Greg was the vice chair of the white-collar defense and corporate investigations practice at an AmLaw 50 firm.   He retired as a lieutenant colonel from the U.S. Army Reserve after 23 years of service as an infantry officer.  Partner Named Lawyer of the Year for Criminal Defense: White-Collar in Sacramento Best Lawyers® in America (2023) Recognized for Criminal Defense: White-Collar Best Lawyers in America (2013-2023) Santa Clara University Santa Clara University School of Law University of California Hastings College of Law University of California Hastings College of Law California Federal Bar Association Sacramento County Bar Association","searchable_name":"McGregor Scott (Greg)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":32,"capability_group_featured":null,"home_page_featured":null},{"id":426596,"version":1,"owner_type":"Person","owner_id":5009,"payload":{"bio":"\u003cp\u003eJacqueline Seidel is a New York-based partner in King \u0026amp; Spalding\u0026rsquo;s Trial \u0026amp; Global Disputes practice.\u0026nbsp; Ms. Seidel defends multi-national companies in complex class and mass action litigation pending in both state and federal court. She frequently\u0026nbsp;partners with clients at the outset of a matter to develop\u0026nbsp;and implement all-inclusive\u0026nbsp;exit strategies for large-scale bet-the-company litigation. Often, such strategies include liaising with clients and virtual law firms to plan a long term, systematic exit strategy and/or global resolution, structuring and implementing court-approved comprehensive settlement programs and successfully resolving large groups of cases.\u0026nbsp;She has also successfully managed - as either national coordinating counsel or as strategic counsel - putative class, mass and individual actions alleging false advertising, unfair business practices, unfair and deceptive trade practices, consumer fraud, consumer protection, and a wide range of common law personal injury and property damage claims.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eIn recognition of her work representing Fortune 500 automotive and pharmaceutical and medical device companies in bet-the-company litigation, she has been named a New York \"Rising Star\" in class action and product liability defense by Super Lawyers.\u003c/p\u003e\n\u003cp\u003eWhile Ms. Seidel has represented clients in a wide range of industries, including the automobile, safety equipment, pharmaceutical, medical device, consumer goods, insurance, reinsurance and media industries, recently her practice has centered on negotiating and executing resolutions of some of the largest and most complex litigations in the automotive industry.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMs. Seidel represented client, Toyota, in its settlements of the \u0026ldquo;unintended acceleration\u0026rdquo; economic loss class actions that involved the consolidation of nearly 200 class actions and required close coordination of efforts with the client\u0026rsquo;s virtual law firm partners handling various aspects of the litigation and governmental/regulatory investigations.\u0026nbsp; At the time this class action litigation was settled, it represented the largest automotive settlement in US history.\u0026nbsp; Ms. Seidel was also involved in the establishment of a court-ordered \u0026ldquo;intensive settlement process\u0026rdquo; for the related personal injury and wrongful death product liability cases.\u0026nbsp; This settlement process effectively resolved the majority of individual product liability cases in the litigation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMs. Seidel also assisted in the negotiations and drafted relevant documents for resolving another billion-dollar class action settlement on behalf of Toyota resulting from the Takata airbag recall that implicated multiple automobile manufacturers and she continues to manage and coordinate roll-out of the multi-year settlement relief.\u0026nbsp; This settlement was finally approved\u0026nbsp;in 2017 and set the tone for subsequent similar settlements by several other auto manufacturers.\u0026nbsp; Ms. Seidel has also successfully resolved other class actions including the Sienna sliding door and Prius IPM class action settlements (the latter\u0026nbsp;is awaiting final approval).\u003c/p\u003e\n\u003cp\u003eRecently, Ms. Seidel was part of the team that successfully resolved hundreds of matters on behalf of an integrated energy company involving product liability allegations related to a certain herbicide.\u0026nbsp; The cases were brought \u0026nbsp;by the litigation\u0026rsquo;s highest-threat plaintiffs\u0026rsquo; counsel and many were pending in one of the most plaintiff-friendly jurisdictions in the country (St Clair County, IL) including a four-case consolidated trial setting that was resolved at the eve of trial.\u0026nbsp; Since the resolution of those cases, thousands of lawsuits have been filed by individuals who were exposed to the product at issue and Ms. Seidel continues\u0026nbsp;to serve as co-strategic counsel in these cases.\u003c/p\u003e","slug":"jacqueline-seidel","email":"jseidel@kslaw.com","phone":null,"matters":["\u003cp\u003eImplemented a strategy to resolve, on behalf of one of the world\u0026rsquo;s largest pharmaceutical companies, a prescription drug litigation involving medication to treat Parkinson's Disease.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;a medical device manufacturer in one of the largest nationwide product liability litigations. Assisted in the development of a comprehensive resolution strategy that effectively decreased the number of active filed cases from thousands to just over one hundred cases. Negotiated and drafted relevant documents for various firm-specific global settlement agreements and negotiated and mediated individual cases to successful resolution in federal and state court.\u003c/p\u003e","\u003cp\u003eOversees and executes on innovative strategy to resolve individual automobile product liability cases in federal multi district litigation, state consolidated litigation and other state court cases through court-ordered intensive settlement programs.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":17,"guid":"17.capabilities","index":0,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":1,"source":"capabilities"},{"id":3,"guid":"3.capabilities","index":2,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":3,"source":"smartTags"},{"id":16,"guid":"16.capabilities","index":4,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":5,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":6,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":7,"source":"capabilities"},{"id":762,"guid":"762.smart_tags","index":8,"source":"smartTags"},{"id":1256,"guid":"1256.smart_tags","index":9,"source":"smartTags"}],"is_active":true,"last_name":"Seidel","nick_name":"Jacquie","clerkships":[],"first_name":"Jacqueline","title_rank":9999,"updated_by":202,"law_schools":[{"id":2619,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"2003-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Recognized as an \"automotive industry expert.\"","detail":"Legal 500 US, 2023"},{"title":"Named a \"Top Attorney Under 40\" - Product Liability","detail":"Law360, 2018"},{"title":"Named a “Rising Star” - Class Action \u0026 Mass Torts","detail":"Super Lawyers, 2015 - 2018"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJacqueline Seidel is a New York-based partner in King \u0026amp; Spalding\u0026rsquo;s Trial \u0026amp; Global Disputes practice.\u0026nbsp; Ms. Seidel defends multi-national companies in complex class and mass action litigation pending in both state and federal court. She frequently\u0026nbsp;partners with clients at the outset of a matter to develop\u0026nbsp;and implement all-inclusive\u0026nbsp;exit strategies for large-scale bet-the-company litigation. Often, such strategies include liaising with clients and virtual law firms to plan a long term, systematic exit strategy and/or global resolution, structuring and implementing court-approved comprehensive settlement programs and successfully resolving large groups of cases.\u0026nbsp;She has also successfully managed - as either national coordinating counsel or as strategic counsel - putative class, mass and individual actions alleging false advertising, unfair business practices, unfair and deceptive trade practices, consumer fraud, consumer protection, and a wide range of common law personal injury and property damage claims.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eIn recognition of her work representing Fortune 500 automotive and pharmaceutical and medical device companies in bet-the-company litigation, she has been named a New York \"Rising Star\" in class action and product liability defense by Super Lawyers.\u003c/p\u003e\n\u003cp\u003eWhile Ms. Seidel has represented clients in a wide range of industries, including the automobile, safety equipment, pharmaceutical, medical device, consumer goods, insurance, reinsurance and media industries, recently her practice has centered on negotiating and executing resolutions of some of the largest and most complex litigations in the automotive industry.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMs. Seidel represented client, Toyota, in its settlements of the \u0026ldquo;unintended acceleration\u0026rdquo; economic loss class actions that involved the consolidation of nearly 200 class actions and required close coordination of efforts with the client\u0026rsquo;s virtual law firm partners handling various aspects of the litigation and governmental/regulatory investigations.\u0026nbsp; At the time this class action litigation was settled, it represented the largest automotive settlement in US history.\u0026nbsp; Ms. Seidel was also involved in the establishment of a court-ordered \u0026ldquo;intensive settlement process\u0026rdquo; for the related personal injury and wrongful death product liability cases.\u0026nbsp; This settlement process effectively resolved the majority of individual product liability cases in the litigation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMs. Seidel also assisted in the negotiations and drafted relevant documents for resolving another billion-dollar class action settlement on behalf of Toyota resulting from the Takata airbag recall that implicated multiple automobile manufacturers and she continues to manage and coordinate roll-out of the multi-year settlement relief.\u0026nbsp; This settlement was finally approved\u0026nbsp;in 2017 and set the tone for subsequent similar settlements by several other auto manufacturers.\u0026nbsp; Ms. Seidel has also successfully resolved other class actions including the Sienna sliding door and Prius IPM class action settlements (the latter\u0026nbsp;is awaiting final approval).\u003c/p\u003e\n\u003cp\u003eRecently, Ms. Seidel was part of the team that successfully resolved hundreds of matters on behalf of an integrated energy company involving product liability allegations related to a certain herbicide.\u0026nbsp; The cases were brought \u0026nbsp;by the litigation\u0026rsquo;s highest-threat plaintiffs\u0026rsquo; counsel and many were pending in one of the most plaintiff-friendly jurisdictions in the country (St Clair County, IL) including a four-case consolidated trial setting that was resolved at the eve of trial.\u0026nbsp; Since the resolution of those cases, thousands of lawsuits have been filed by individuals who were exposed to the product at issue and Ms. Seidel continues\u0026nbsp;to serve as co-strategic counsel in these cases.\u003c/p\u003e","matters":["\u003cp\u003eImplemented a strategy to resolve, on behalf of one of the world\u0026rsquo;s largest pharmaceutical companies, a prescription drug litigation involving medication to treat Parkinson's Disease.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;a medical device manufacturer in one of the largest nationwide product liability litigations. Assisted in the development of a comprehensive resolution strategy that effectively decreased the number of active filed cases from thousands to just over one hundred cases. Negotiated and drafted relevant documents for various firm-specific global settlement agreements and negotiated and mediated individual cases to successful resolution in federal and state court.\u003c/p\u003e","\u003cp\u003eOversees and executes on innovative strategy to resolve individual automobile product liability cases in federal multi district litigation, state consolidated litigation and other state court cases through court-ordered intensive settlement programs.\u003c/p\u003e"],"recognitions":[{"title":"Recognized as an \"automotive industry expert.\"","detail":"Legal 500 US, 2023"},{"title":"Named a \"Top Attorney Under 40\" - Product Liability","detail":"Law360, 2018"},{"title":"Named a “Rising Star” - Class Action \u0026 Mass Torts","detail":"Super Lawyers, 2015 - 2018"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":5142}]},"capability_group_id":3},"created_at":"2025-05-26T04:55:06.000Z","updated_at":"2025-05-26T04:55:06.000Z","searchable_text":"Seidel{{ FIELD }}{:title=\u0026gt;\"Recognized as an \\\"automotive industry expert.\\\"\", :detail=\u0026gt;\"Legal 500 US, 2023\"}{{ FIELD }}{:title=\u0026gt;\"Named a \\\"Top Attorney Under 40\\\" - Product Liability\", :detail=\u0026gt;\"Law360, 2018\"}{{ FIELD }}{:title=\u0026gt;\"Named a “Rising Star” - Class Action \u0026amp; Mass Torts\", :detail=\u0026gt;\"Super Lawyers, 2015 - 2018\"}{{ FIELD }}Implemented a strategy to resolve, on behalf of one of the world’s largest pharmaceutical companies, a prescription drug litigation involving medication to treat Parkinson's Disease.{{ FIELD }}Represented a medical device manufacturer in one of the largest nationwide product liability litigations. Assisted in the development of a comprehensive resolution strategy that effectively decreased the number of active filed cases from thousands to just over one hundred cases. Negotiated and drafted relevant documents for various firm-specific global settlement agreements and negotiated and mediated individual cases to successful resolution in federal and state court.{{ FIELD }}Oversees and executes on innovative strategy to resolve individual automobile product liability cases in federal multi district litigation, state consolidated litigation and other state court cases through court-ordered intensive settlement programs.{{ FIELD }}Jacqueline Seidel is a New York-based partner in King \u0026amp; Spalding’s Trial \u0026amp; Global Disputes practice.  Ms. Seidel defends multi-national companies in complex class and mass action litigation pending in both state and federal court. She frequently partners with clients at the outset of a matter to develop and implement all-inclusive exit strategies for large-scale bet-the-company litigation. Often, such strategies include liaising with clients and virtual law firms to plan a long term, systematic exit strategy and/or global resolution, structuring and implementing court-approved comprehensive settlement programs and successfully resolving large groups of cases. She has also successfully managed - as either national coordinating counsel or as strategic counsel - putative class, mass and individual actions alleging false advertising, unfair business practices, unfair and deceptive trade practices, consumer fraud, consumer protection, and a wide range of common law personal injury and property damage claims.\nIn recognition of her work representing Fortune 500 automotive and pharmaceutical and medical device companies in bet-the-company litigation, she has been named a New York \"Rising Star\" in class action and product liability defense by Super Lawyers.\nWhile Ms. Seidel has represented clients in a wide range of industries, including the automobile, safety equipment, pharmaceutical, medical device, consumer goods, insurance, reinsurance and media industries, recently her practice has centered on negotiating and executing resolutions of some of the largest and most complex litigations in the automotive industry. \nMs. Seidel represented client, Toyota, in its settlements of the “unintended acceleration” economic loss class actions that involved the consolidation of nearly 200 class actions and required close coordination of efforts with the client’s virtual law firm partners handling various aspects of the litigation and governmental/regulatory investigations.  At the time this class action litigation was settled, it represented the largest automotive settlement in US history.  Ms. Seidel was also involved in the establishment of a court-ordered “intensive settlement process” for the related personal injury and wrongful death product liability cases.  This settlement process effectively resolved the majority of individual product liability cases in the litigation. \nMs. Seidel also assisted in the negotiations and drafted relevant documents for resolving another billion-dollar class action settlement on behalf of Toyota resulting from the Takata airbag recall that implicated multiple automobile manufacturers and she continues to manage and coordinate roll-out of the multi-year settlement relief.  This settlement was finally approved in 2017 and set the tone for subsequent similar settlements by several other auto manufacturers.  Ms. Seidel has also successfully resolved other class actions including the Sienna sliding door and Prius IPM class action settlements (the latter is awaiting final approval).\nRecently, Ms. Seidel was part of the team that successfully resolved hundreds of matters on behalf of an integrated energy company involving product liability allegations related to a certain herbicide.  The cases were brought  by the litigation’s highest-threat plaintiffs’ counsel and many were pending in one of the most plaintiff-friendly jurisdictions in the country (St Clair County, IL) including a four-case consolidated trial setting that was resolved at the eve of trial.  Since the resolution of those cases, thousands of lawsuits have been filed by individuals who were exposed to the product at issue and Ms. Seidel continues to serve as co-strategic counsel in these cases. Partner Recognized as an \"automotive industry expert.\" Legal 500 US, 2023 Named a \"Top Attorney Under 40\" - Product Liability Law360, 2018 Named a “Rising Star” - Class Action \u0026amp; Mass Torts Super Lawyers, 2015 - 2018 Columbia University Columbia University School of Law Yeshiva University Benjamin N. Cardozo School of Law U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York Implemented a strategy to resolve, on behalf of one of the world’s largest pharmaceutical companies, a prescription drug litigation involving medication to treat Parkinson's Disease. Represented a medical device manufacturer in one of the largest nationwide product liability litigations. Assisted in the development of a comprehensive resolution strategy that effectively decreased the number of active filed cases from thousands to just over one hundred cases. Negotiated and drafted relevant documents for various firm-specific global settlement agreements and negotiated and mediated individual cases to successful resolution in federal and state court. Oversees and executes on innovative strategy to resolve individual automobile product liability cases in federal multi district litigation, state consolidated litigation and other state court cases through court-ordered intensive settlement programs.","searchable_name":"Jacqueline Seidel (Jacquie)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":442375,"version":1,"owner_type":"Person","owner_id":923,"payload":{"bio":"\u003cp\u003eJohn Shakow\u0026nbsp;focuses on complex regulatory, commercial, investigation and litigation issues related to pharmaceutical government pricing and price reporting. A Chambers-ranked partner in our FDA and Life Sciences practice and co-chair of the firm's Life Sciences \u0026amp; Healthcare Industry Group, John represents pharmaceutical and biotechnology manufacturers in every facet of government drug payor program compliance and liability mitigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJohn has over 25 years'\u0026nbsp;experience in helping pharmaceutical and biotechnology clients resolve commercial and organizational challenges while maintaining the integrity of their price-reporting compliance efforts.\u003c/p\u003e\n\u003cp\u003eHe counsels clients on their rights and obligations under Medicaid, Medicare,340B, VA/FSS and related programs, and regularly assists them in interactions with the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, the Department of Health and Human Services Office of Inspector General, and the Veterans Administration.\u003c/p\u003e\n\u003cp\u003eJohn often conducts in-depth pricing assessments to develop and implement government price calculation and reporting policies, procedures, systems and methodologies. John has overseen\u0026nbsp;dozens of substantial\u0026nbsp;\u003cem\u003ebona fide\u003c/em\u003e\u0026nbsp;service fee analysis projects for large and small drug manufacturers. He is experienced in managing the coordination and integration of pricing methodologies in major pharmaceutical mergers.\u003c/p\u003e\n\u003cp\u003eJohn has significant pharmaceutical litigation and investigation experience. He regularly challenges government agencies' positions on drug pricing and reimbursement matters, and defends clients in federal and state investigations related to price reporting. John represents manufacturers in 340B, IRA, and Medicaid Drug Rebate Program litigation, and has counseled drug manufacturers before the House Energy \u0026amp; Commerce and Senate Finance committees in drug-pricing investigations and inquiries.\u003c/p\u003e","slug":"john-shakow","email":"jshakow@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":179}]},"expertise":[{"id":103,"guid":"103.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":2,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":3,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":4,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":5,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":6,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":7,"source":"smartTags"},{"id":133,"guid":"133.capabilities","index":8,"source":"capabilities"}],"is_active":true,"last_name":"Shakow","nick_name":"John","clerkships":[],"first_name":"John","title_rank":9999,"updated_by":35,"law_schools":[],"middle_name":"D.","name_suffix":"","recognitions":[{"title":"“John is extremely strong and extremely client-focused.”","detail":"CHAMBERS USA, 2022"},{"title":"“Top Ranked Lawyer,” Healthcare: Pharmaceutical/Medical Products Regulatory","detail":"CHAMBERS USA, 2021, 2022, 2023 and 2024"},{"title":"Recommended Key Lawyer: 2021, 2022, 2023","detail":"Legal 500"},{"title":"Shortlist for Regulatory Attorney of the Year: Pricing \u0026 Reimbursement, 2017-2023","detail":"LMG Life Sciences"},{"title":"2016 Lifetime Achievement Award","detail":"Institute for International Research's Medicaid Drug Rebate Program"},{"title":"Life Sciences Star: Pricing and Reimbursement, 2012 to 2018","detail":"Guide to Leading Life Sciences Firms and Attorneys in North America"}],"linked_in_url":"https://www.linkedin.com/in/JohnShakow/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJohn Shakow\u0026nbsp;focuses on complex regulatory, commercial, investigation and litigation issues related to pharmaceutical government pricing and price reporting. A Chambers-ranked partner in our FDA and Life Sciences practice and co-chair of the firm's Life Sciences \u0026amp; Healthcare Industry Group, John represents pharmaceutical and biotechnology manufacturers in every facet of government drug payor program compliance and liability mitigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJohn has over 25 years'\u0026nbsp;experience in helping pharmaceutical and biotechnology clients resolve commercial and organizational challenges while maintaining the integrity of their price-reporting compliance efforts.\u003c/p\u003e\n\u003cp\u003eHe counsels clients on their rights and obligations under Medicaid, Medicare,340B, VA/FSS and related programs, and regularly assists them in interactions with the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, the Department of Health and Human Services Office of Inspector General, and the Veterans Administration.\u003c/p\u003e\n\u003cp\u003eJohn often conducts in-depth pricing assessments to develop and implement government price calculation and reporting policies, procedures, systems and methodologies. John has overseen\u0026nbsp;dozens of substantial\u0026nbsp;\u003cem\u003ebona fide\u003c/em\u003e\u0026nbsp;service fee analysis projects for large and small drug manufacturers. He is experienced in managing the coordination and integration of pricing methodologies in major pharmaceutical mergers.\u003c/p\u003e\n\u003cp\u003eJohn has significant pharmaceutical litigation and investigation experience. He regularly challenges government agencies' positions on drug pricing and reimbursement matters, and defends clients in federal and state investigations related to price reporting. John represents manufacturers in 340B, IRA, and Medicaid Drug Rebate Program litigation, and has counseled drug manufacturers before the House Energy \u0026amp; Commerce and Senate Finance committees in drug-pricing investigations and inquiries.\u003c/p\u003e","recognitions":[{"title":"“John is extremely strong and extremely client-focused.”","detail":"CHAMBERS USA, 2022"},{"title":"“Top Ranked Lawyer,” Healthcare: Pharmaceutical/Medical Products Regulatory","detail":"CHAMBERS USA, 2021, 2022, 2023 and 2024"},{"title":"Recommended Key Lawyer: 2021, 2022, 2023","detail":"Legal 500"},{"title":"Shortlist for Regulatory Attorney of the Year: Pricing \u0026 Reimbursement, 2017-2023","detail":"LMG Life Sciences"},{"title":"2016 Lifetime Achievement Award","detail":"Institute for International Research's Medicaid Drug Rebate Program"},{"title":"Life Sciences Star: Pricing and Reimbursement, 2012 to 2018","detail":"Guide to Leading Life Sciences Firms and Attorneys in North America"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11649}]},"capability_group_id":2},"created_at":"2025-11-05T05:03:46.000Z","updated_at":"2025-11-05T05:03:46.000Z","searchable_text":"Shakow{{ FIELD }}{:title=\u0026gt;\"“John is extremely strong and extremely client-focused.”\", :detail=\u0026gt;\"CHAMBERS USA, 2022\"}{{ FIELD }}{:title=\u0026gt;\"“Top Ranked Lawyer,” Healthcare: Pharmaceutical/Medical Products Regulatory\", :detail=\u0026gt;\"CHAMBERS USA, 2021, 2022, 2023 and 2024\"}{{ FIELD }}{:title=\u0026gt;\"Recommended Key Lawyer: 2021, 2022, 2023\", :detail=\u0026gt;\"Legal 500\"}{{ FIELD }}{:title=\u0026gt;\"Shortlist for Regulatory Attorney of the Year: Pricing \u0026amp; Reimbursement, 2017-2023\", :detail=\u0026gt;\"LMG Life Sciences\"}{{ FIELD }}{:title=\u0026gt;\"2016 Lifetime Achievement Award\", :detail=\u0026gt;\"Institute for International Research's Medicaid Drug Rebate Program\"}{{ FIELD }}{:title=\u0026gt;\"Life Sciences Star: Pricing and Reimbursement, 2012 to 2018\", :detail=\u0026gt;\"Guide to Leading Life Sciences Firms and Attorneys in North America\"}{{ FIELD }}John Shakow focuses on complex regulatory, commercial, investigation and litigation issues related to pharmaceutical government pricing and price reporting. A Chambers-ranked partner in our FDA and Life Sciences practice and co-chair of the firm's Life Sciences \u0026amp; Healthcare Industry Group, John represents pharmaceutical and biotechnology manufacturers in every facet of government drug payor program compliance and liability mitigation.\nJohn has over 25 years' experience in helping pharmaceutical and biotechnology clients resolve commercial and organizational challenges while maintaining the integrity of their price-reporting compliance efforts.\nHe counsels clients on their rights and obligations under Medicaid, Medicare,340B, VA/FSS and related programs, and regularly assists them in interactions with the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, the Department of Health and Human Services Office of Inspector General, and the Veterans Administration.\nJohn often conducts in-depth pricing assessments to develop and implement government price calculation and reporting policies, procedures, systems and methodologies. John has overseen dozens of substantial bona fide service fee analysis projects for large and small drug manufacturers. He is experienced in managing the coordination and integration of pricing methodologies in major pharmaceutical mergers.\nJohn has significant pharmaceutical litigation and investigation experience. He regularly challenges government agencies' positions on drug pricing and reimbursement matters, and defends clients in federal and state investigations related to price reporting. John represents manufacturers in 340B, IRA, and Medicaid Drug Rebate Program litigation, and has counseled drug manufacturers before the House Energy \u0026amp; Commerce and Senate Finance committees in drug-pricing investigations and inquiries. John D Shakow Partner “John is extremely strong and extremely client-focused.” CHAMBERS USA, 2022 “Top Ranked Lawyer,” Healthcare: Pharmaceutical/Medical Products Regulatory CHAMBERS USA, 2021, 2022, 2023 and 2024 Recommended Key Lawyer: 2021, 2022, 2023 Legal 500 Shortlist for Regulatory Attorney of the Year: Pricing \u0026amp; Reimbursement, 2017-2023 LMG Life Sciences 2016 Lifetime Achievement Award Institute for International Research's Medicaid Drug Rebate Program Life Sciences Star: Pricing and Reimbursement, 2012 to 2018 Guide to Leading Life Sciences Firms and Attorneys in North America Swarthmore College  University of Virginia University of Virginia School of Law U.S. Court of Appeals for the Ninth Circuit U.S. Court of Appeals for the D.C. Circuit U.S. District Court for the Eastern District of Virginia U.S. District Court for the Central District of Illinois U.S. District Court for the District of Columbia District of Columbia Virginia District of Columbia Bar State Bar of Virginia","searchable_name":"John D. Shakow","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":427262,"version":1,"owner_type":"Person","owner_id":6596,"payload":{"bio":"\u003cp\u003eJeff has 30 years\u0026rsquo; experience in US medical device law and regulation. \u0026nbsp;He counsels firms in regulatory strategy and filings, including presubmissions, clearances, approvals, breakthrough designations, and internal agency appeals.\u0026nbsp; He helps firms develop a sound regulatory strategy for bringing their medical devices through US FDA review, to draft the relevant submissions, and to respond to FDA\u0026rsquo;s requests for information and data.\u0026nbsp; When advising start-ups and mid-sized manufacturers, Jeffrey recognizes the business considerations involved in creating regulatory strategies and managing compliance.\u0026nbsp; His mission is to bring companies through the FDA process as efficiently and expeditiously as possible.\u0026nbsp; Jeffrey also counsels companies on post-market compliance, such as reporting to FDA, complying with the quality system regulation, labeling and advertising compliance, recalls, inspections, and warning letters, and he is an expert in FDA\u0026rsquo;s regulation of combination products (e.g., drug-device combinations).[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJeff is a national authority on FDA\u0026rsquo;s regulation of medical devices, combination products, and HCT/Ps.\u0026nbsp; He actively contributes to industry conversations on FDA regulation of medical devices. He has published hundreds of articles on various topics relating to FDA\u0026rsquo;s regulation of medical devices.\u003c/p\u003e\n\u003cp\u003eHe is a past member of the Editorial Advisory Board for both\u0026nbsp;\u003cem\u003eMDDI\u0026nbsp;\u003c/em\u003eand\u0026nbsp;\u003cem\u003eUpdate\u0026nbsp;\u003c/em\u003emagazines, co-editor of two textbooks,\u0026nbsp;\u003cem\u003ePromotion of Biomedical Products\u0026nbsp;\u003c/em\u003e(Food and Drug Law Institute, 2006) and\u0026nbsp;\u003cem\u003eCombination Products, How to Develop the Optimal Strategic Path for Approval\u0026nbsp;\u003c/em\u003e(FDA News 2005).\u0026nbsp; He has contributed chapters to several textbooks, including\u0026nbsp;\u003cem\u003eMedical Devices Law and Regulation Answer Book\u003c/em\u003e\u0026nbsp;(Practising Law Institute 2023 ed.).\u003c/p\u003e\n\u003cp\u003eJeff was a Lecturer and Fischell Literati teaching the University of Maryland\u0026rsquo;s Regulatory Law: Medical Devices course. He has served on the Medical Devices and Diagnostics Committee, Food and Drug Law Institute.\u003c/p\u003e","slug":"jeffrey-shapiro","email":"jshapiro@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":21,"guid":"21.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":112,"guid":"112.capabilities","index":3,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":4,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":5,"source":"smartTags"},{"id":826,"guid":"826.smart_tags","index":6,"source":"smartTags"}],"is_active":true,"last_name":"Shapiro","nick_name":"Jeffrey","clerkships":[],"first_name":"Jeffrey","title_rank":9999,"updated_by":35,"law_schools":[{"id":824,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"1986-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"K.","name_suffix":"","recognitions":[{"title":"Life Sciences Key Lawyer","detail":"The Legal 500 (2024)"},{"title":"Life Science Star","detail":"LMG Life Sciences, 2012 – 2023"},{"title":"DC Super Lawyer","detail":"Super Lawyers, 2014 – 2023"},{"title":"The International Who’s Who of Business Lawyers – Life Sciences","detail":"Who’s Who Legal, 2014 – 2023"},{"title":"Nominee for Regulatory Attorney of the Year","detail":"LMG Life Sciences, 2017"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJeff has 30 years\u0026rsquo; experience in US medical device law and regulation. \u0026nbsp;He counsels firms in regulatory strategy and filings, including presubmissions, clearances, approvals, breakthrough designations, and internal agency appeals.\u0026nbsp; He helps firms develop a sound regulatory strategy for bringing their medical devices through US FDA review, to draft the relevant submissions, and to respond to FDA\u0026rsquo;s requests for information and data.\u0026nbsp; When advising start-ups and mid-sized manufacturers, Jeffrey recognizes the business considerations involved in creating regulatory strategies and managing compliance.\u0026nbsp; His mission is to bring companies through the FDA process as efficiently and expeditiously as possible.\u0026nbsp; Jeffrey also counsels companies on post-market compliance, such as reporting to FDA, complying with the quality system regulation, labeling and advertising compliance, recalls, inspections, and warning letters, and he is an expert in FDA\u0026rsquo;s regulation of combination products (e.g., drug-device combinations).[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJeff is a national authority on FDA\u0026rsquo;s regulation of medical devices, combination products, and HCT/Ps.\u0026nbsp; He actively contributes to industry conversations on FDA regulation of medical devices. He has published hundreds of articles on various topics relating to FDA\u0026rsquo;s regulation of medical devices.\u003c/p\u003e\n\u003cp\u003eHe is a past member of the Editorial Advisory Board for both\u0026nbsp;\u003cem\u003eMDDI\u0026nbsp;\u003c/em\u003eand\u0026nbsp;\u003cem\u003eUpdate\u0026nbsp;\u003c/em\u003emagazines, co-editor of two textbooks,\u0026nbsp;\u003cem\u003ePromotion of Biomedical Products\u0026nbsp;\u003c/em\u003e(Food and Drug Law Institute, 2006) and\u0026nbsp;\u003cem\u003eCombination Products, How to Develop the Optimal Strategic Path for Approval\u0026nbsp;\u003c/em\u003e(FDA News 2005).\u0026nbsp; He has contributed chapters to several textbooks, including\u0026nbsp;\u003cem\u003eMedical Devices Law and Regulation Answer Book\u003c/em\u003e\u0026nbsp;(Practising Law Institute 2023 ed.).\u003c/p\u003e\n\u003cp\u003eJeff was a Lecturer and Fischell Literati teaching the University of Maryland\u0026rsquo;s Regulatory Law: Medical Devices course. He has served on the Medical Devices and Diagnostics Committee, Food and Drug Law Institute.\u003c/p\u003e","recognitions":[{"title":"Life Sciences Key Lawyer","detail":"The Legal 500 (2024)"},{"title":"Life Science Star","detail":"LMG Life Sciences, 2012 – 2023"},{"title":"DC Super Lawyer","detail":"Super Lawyers, 2014 – 2023"},{"title":"The International Who’s Who of Business Lawyers – Life Sciences","detail":"Who’s Who Legal, 2014 – 2023"},{"title":"Nominee for Regulatory Attorney of the Year","detail":"LMG Life Sciences, 2017"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11031}]},"capability_group_id":2},"created_at":"2025-05-26T04:59:28.000Z","updated_at":"2025-05-26T04:59:28.000Z","searchable_text":"Shapiro{{ FIELD }}{:title=\u0026gt;\"Life Sciences Key Lawyer\", :detail=\u0026gt;\"The Legal 500 (2024)\"}{{ FIELD }}{:title=\u0026gt;\"Life Science Star\", :detail=\u0026gt;\"LMG Life Sciences, 2012 – 2023\"}{{ FIELD }}{:title=\u0026gt;\"DC Super Lawyer\", :detail=\u0026gt;\"Super Lawyers, 2014 – 2023\"}{{ FIELD }}{:title=\u0026gt;\"The International Who’s Who of Business Lawyers – Life Sciences\", :detail=\u0026gt;\"Who’s Who Legal, 2014 – 2023\"}{{ FIELD }}{:title=\u0026gt;\"Nominee for Regulatory Attorney of the Year\", :detail=\u0026gt;\"LMG Life Sciences, 2017\"}{{ FIELD }}Jeff has 30 years’ experience in US medical device law and regulation.  He counsels firms in regulatory strategy and filings, including presubmissions, clearances, approvals, breakthrough designations, and internal agency appeals.  He helps firms develop a sound regulatory strategy for bringing their medical devices through US FDA review, to draft the relevant submissions, and to respond to FDA’s requests for information and data.  When advising start-ups and mid-sized manufacturers, Jeffrey recognizes the business considerations involved in creating regulatory strategies and managing compliance.  His mission is to bring companies through the FDA process as efficiently and expeditiously as possible.  Jeffrey also counsels companies on post-market compliance, such as reporting to FDA, complying with the quality system regulation, labeling and advertising compliance, recalls, inspections, and warning letters, and he is an expert in FDA’s regulation of combination products (e.g., drug-device combinations).\nJeff is a national authority on FDA’s regulation of medical devices, combination products, and HCT/Ps.  He actively contributes to industry conversations on FDA regulation of medical devices. He has published hundreds of articles on various topics relating to FDA’s regulation of medical devices.\nHe is a past member of the Editorial Advisory Board for both MDDI and Update magazines, co-editor of two textbooks, Promotion of Biomedical Products (Food and Drug Law Institute, 2006) and Combination Products, How to Develop the Optimal Strategic Path for Approval (FDA News 2005).  He has contributed chapters to several textbooks, including Medical Devices Law and Regulation Answer Book (Practising Law Institute 2023 ed.).\nJeff was a Lecturer and Fischell Literati teaching the University of Maryland’s Regulatory Law: Medical Devices course. He has served on the Medical Devices and Diagnostics Committee, Food and Drug Law Institute. Partner Life Sciences Key Lawyer The Legal 500 (2024) Life Science Star LMG Life Sciences, 2012 – 2023 DC Super Lawyer Super Lawyers, 2014 – 2023 The International Who’s Who of Business Lawyers – Life Sciences Who’s Who Legal, 2014 – 2023 Nominee for Regulatory Attorney of the Year LMG Life Sciences, 2017 Brown University  Harvard University Harvard Law School District of Columbia","searchable_name":"Jeffrey K. Shapiro","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":442418,"version":1,"owner_type":"Person","owner_id":1470,"payload":{"bio":"\u003cp\u003eDarren focuses his practice on the defense of\u0026nbsp;high-stakes\u0026nbsp;ERISA litigation matters.\u0026nbsp; He defends leading companies\u0026nbsp;in a variety of ERISA class actions involving retirement\u0026nbsp;plan investments, breach of fiduciary duty claims, and other complex employee benefits disputes.\u0026nbsp;Darren also counsels clients in connection with governmental investigations involving employee benefit plans and assists clients with disputes and investigations involving executive compensation arrangements.\u0026nbsp; Darren has been recognized\u0026nbsp;as a Next Generation Lawyer by\u0026nbsp;\u003cem\u003eThe Legal 500\u003c/em\u003e\u0026nbsp;for ERISA Litigation in each of the last five years.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDarren's representative clients include The Coca-Cola Company, The Home Depot, Bank of America, SunTrust Banks, Waste Management, and Aon Corporation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eHe graduated, \u003cem\u003emagna cum laude\u003c/em\u003e, from The University of Tennessee College of Law, where he was elected to the Order of the Coif.\u0026nbsp;\u003c/p\u003e","slug":"darren-shuler","email":"dshuler@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":502,"guid":"502.smart_tags","index":1,"source":"smartTags"},{"id":3,"guid":"3.capabilities","index":2,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":3,"source":"capabilities"},{"id":121,"guid":"121.capabilities","index":4,"source":"capabilities"},{"id":15,"guid":"15.capabilities","index":5,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":6,"source":"capabilities"},{"id":19,"guid":"19.capabilities","index":7,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":8,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":9,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":10,"source":"capabilities"}],"is_active":true,"last_name":"Shuler","nick_name":"Darren","clerkships":[],"first_name":"Darren","title_rank":9999,"updated_by":35,"law_schools":[],"middle_name":"A.","name_suffix":"","recognitions":[{"title":"Named a Next Generation Lawyer for ERISA Litigation","detail":"Legal 500 US, 2020, 2021, 2022, and 2023"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eDarren focuses his practice on the defense of\u0026nbsp;high-stakes\u0026nbsp;ERISA litigation matters.\u0026nbsp; He defends leading companies\u0026nbsp;in a variety of ERISA class actions involving retirement\u0026nbsp;plan investments, breach of fiduciary duty claims, and other complex employee benefits disputes.\u0026nbsp;Darren also counsels clients in connection with governmental investigations involving employee benefit plans and assists clients with disputes and investigations involving executive compensation arrangements.\u0026nbsp; Darren has been recognized\u0026nbsp;as a Next Generation Lawyer by\u0026nbsp;\u003cem\u003eThe Legal 500\u003c/em\u003e\u0026nbsp;for ERISA Litigation in each of the last five years.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDarren's representative clients include The Coca-Cola Company, The Home Depot, Bank of America, SunTrust Banks, Waste Management, and Aon Corporation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eHe graduated, \u003cem\u003emagna cum laude\u003c/em\u003e, from The University of Tennessee College of Law, where he was elected to the Order of the Coif.\u0026nbsp;\u003c/p\u003e","recognitions":[{"title":"Named a Next Generation Lawyer for ERISA Litigation","detail":"Legal 500 US, 2020, 2021, 2022, and 2023"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11829}]},"capability_group_id":3},"created_at":"2025-11-05T05:04:54.000Z","updated_at":"2025-11-05T05:04:54.000Z","searchable_text":"Shuler{{ FIELD }}{:title=\u0026gt;\"Named a Next Generation Lawyer for ERISA Litigation\", :detail=\u0026gt;\"Legal 500 US, 2020, 2021, 2022, and 2023\"}{{ FIELD }}Darren focuses his practice on the defense of high-stakes ERISA litigation matters.  He defends leading companies in a variety of ERISA class actions involving retirement plan investments, breach of fiduciary duty claims, and other complex employee benefits disputes. Darren also counsels clients in connection with governmental investigations involving employee benefit plans and assists clients with disputes and investigations involving executive compensation arrangements.  Darren has been recognized as a Next Generation Lawyer by The Legal 500 for ERISA Litigation in each of the last five years. \nDarren's representative clients include The Coca-Cola Company, The Home Depot, Bank of America, SunTrust Banks, Waste Management, and Aon Corporation. \nHe graduated, magna cum laude, from The University of Tennessee College of Law, where he was elected to the Order of the Coif.  Partner Named a Next Generation Lawyer for ERISA Litigation Legal 500 US, 2020, 2021, 2022, and 2023 Maryville College  The University of Tennessee University of Tennessee College of Law University of Georgia University of Georgia School of Law Florida Georgia State Bar of Georgia State Bar of Florida","searchable_name":"Darren A. Shuler","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":444020,"version":1,"owner_type":"Person","owner_id":2024,"payload":{"bio":"\u003cp\u003eElizabeth is the Co-Head of the firm's International Disputes Practice Group.\u0026nbsp; With particular knowledge of\u0026nbsp;the\u0026nbsp;energy, tech, and pharma industries, Elizabeth represents clients in high-profile disputes involving major\u0026nbsp;projects and long-term foreign investments.\u0026nbsp; Her cases are regularly at the cutting edge of international arbitration practice, and several exceed USD 1 billion in dispute.\u0026nbsp; Elizabeth is licensed to practice in New York, Georgia, and Texas, and has repeated experience in disputes involving the governing laws of the U.S., England, and various jurisdictions in Europe and Asia.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eElizabeth solves cross-border problems for her clients, having represented\u0026nbsp;clients in dozens of investor-State and commercial arbitrations and disputes.\u0026nbsp; She specializes in complex cases involving multiple parties,\u0026nbsp;government\u0026nbsp;entities, and cross-jurisdictional aspects.\u0026nbsp; Her counsel experience includes arbitrations convened under the AAA/ICDR, CPR, ICC, ICSID, LCIA, SIAC, and UNCITRAL Arbitration Rules, and practice in U.S. federal courts.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eElizabeth is particularly familiar with the legal and technical aspects of disputes in the energy, tech, and pharma industries.\u0026nbsp; She has handled numerous cases arising from long-term contracts (sale and purchase, supply, production sharing, concession,\u0026nbsp;EPC, licensing, etc.), deepening her knowledge not only of the contractual frameworks but also the practical and logistical\u0026nbsp;aspects of long-term investment projects.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eShe has experience coordinating parallel proceedings in \"viral\" disputes, including cross-border litigations, Section 1782 discovery, commercial and treaty arbitrations, and injunction and enforcement proceedings.\u0026nbsp; She also has significant experience representing major investors in treaty-based claims against States, and she regularly provides pre-dispute advice on foreign investment protection\u0026nbsp;and treaty analysis.\u003c/p\u003e\n\u003cp\u003eAlong with other accolades for her advocacy and client service, Global Arbitration Review selected Elizabeth for their\u0026nbsp;\"45 under 45\" global survey, and\u0026nbsp;Legal 500 named her a\u0026nbsp;\"Leading Lawyer\" in 2025.\u0026nbsp; In addition to her practice and frequent contributions as a speaker and author, Elizabeth acts as an Adjunct Law Professor at Emory University School of Law.\u0026nbsp; She is also committed to youth development in her community, and currently\u0026nbsp;serves\u0026nbsp;on the Board of Directors for the Boys \u0026amp; Girls Club of Metro Atlanta.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e","slug":"elizabeth-silbert","email":"esilbert@kslaw.com","phone":null,"matters":["\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003eThe Coca-Cola Company\u003c/strong\u003e\u0026nbsp;in a Europe-based commercial arbitration under a long-term sponsorship agreement.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eChevron Thailand Exploration \u0026amp; Production Co\u003c/strong\u003e. in an ad hoc arbitration against the Kingdom of Thailand and the Ministry of Energy of Thailand, concerning a dispute in excess of US$ 2 billion regarding the decommissioning of offshore assets in the Gulf of Thailand.\u003c/p\u003e","\u003cp\u003eObtained a declaratory award worth more than US$1 billion for a\u0026nbsp;\u003cstrong\u003emajor Asia-based power consortium\u003c/strong\u003e\u0026nbsp;in a SIAC arbitration seated in Singapore, concerning a contractual dispute in the power transmission industry.\u003c/p\u003e","\u003cp\u003eRepresenting a\u0026nbsp;\u003cstrong\u003eEuropean trading company\u003c/strong\u003e\u0026nbsp;in a commercial arbitration seated in New York, concerning US$ 500 million breach of contract claims under various corporate and shareholders' agreements in a South American joint venture.\u003c/p\u003e","\u003cp\u003eObtained a declaratory award worth more than US$ 600 million on behalf of a\u0026nbsp;\u003cstrong\u003emajor U.S. LNG company\u003c/strong\u003e\u0026nbsp;in a AAA arbitration seated in Houston, concerning various breach-of-contract claims.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003eChevron Corporation\u003c/strong\u003e\u0026nbsp;in a treaty arbitration against the Republic of Ecuador seated in The Hague, concerning the US$9 billion \"Lago Agrio\" environmental judgment issued by the Ecuadorian courts, resulting in precedent-setting awards in favor of Chevron, including a finding of denial of justice and treaty breaches by Ecuador's courts, as well as numerous interim measures awards ordering Ecuador to prevent enforcement of the court judgment.\u003c/p\u003e","\u003cp\u003eWon an award for declaratory relief worth over $4 billion in an ICC arbitration on behalf of\u0026nbsp;\u003cstrong\u003etwo international oil majors\u0026nbsp;\u003c/strong\u003eagainst a Southeast Asian government, arising out of a revenue-allocation dispute under a gas service contract.\u003c/p\u003e","\u003cp\u003eObtained a denial of Section 1782 discovery in aid of a foreign commercial arbitration on behalf of\u0026nbsp;\u003cstrong\u003eHalliburton Company\u0026nbsp;\u003c/strong\u003efrom the U.S. District Court of a Delaware, including affirmance on appeal before the Third Circuit.\u003c/p\u003e","\u003cp\u003eWon a US$ 158 million award on behalf of\u0026nbsp;\u003cstrong\u003eGE-Hitachi Nuclear Energy Americas LLC\u003c/strong\u003e\u0026nbsp;in an ICC arbitration against a national power company seated in Taiwan, involving contractual and technical claims related to the construction of a nuclear power plant.\u003c/p\u003e","\u003cp\u003eWon a US$ 85 million award on behalf of\u0026nbsp;\u003cstrong\u003ea major U.S. energy company\u003c/strong\u003e\u0026nbsp;in an UNCITRAL arbitration seated in London, concerning breach-of-contract claims related to a gas pipeline project in Indonesia.\u003c/p\u003e","\u003cp\u003eWon a declaratory award (with costs) worth approximately US$ 1.5 billion on behalf of\u0026nbsp;\u003cstrong\u003ea U.S. LNG company,\u0026nbsp;\u003c/strong\u003ein an ICDR arbitration seated in New York concerning the terms of a long-term tolling agreement.\u003c/p\u003e","\u003cp\u003eWon a US$ 96 million final award on behalf of\u0026nbsp;\u003cstrong\u003eChevron Corporation\u003c/strong\u003e\u0026nbsp;in an UNCITRAL arbitration against the Republic of Ecuador seated in The Hague related to undue delays by Ecuadorian courts, including assistance in successful defense against set-aside proceedings in The Netherlands through all levels of appeals.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eShell Philippines Exploration B.V\u003c/strong\u003e\u003cstrong\u003e.\u003c/strong\u003e\u0026nbsp;in a multi-billion-dollar ICSID arbitration against the Republic of the Philippines under the Netherlands-Philippines bilateral investment treaty concerning the mistreatment of Shell\u0026rsquo;s investment in the Malampaya gas-to-power project.\u003c/p\u003e","\u003cp\u003eObtained favorable settlement on behalf of\u0026nbsp;\u003cstrong\u003ea European technology company\u003c/strong\u003e\u0026nbsp;in an ICDR arbitration seated in London, concerning a software licensing dispute.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3534}]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":14,"guid":"14.capabilities","index":1,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":2,"source":"capabilities"},{"id":4,"guid":"4.capabilities","index":3,"source":"capabilities"},{"id":35,"guid":"35.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":104,"guid":"104.capabilities","index":6,"source":"capabilities"},{"id":132,"guid":"132.capabilities","index":7,"source":"capabilities"},{"id":1472,"guid":"1472.smart_tags","index":8,"source":"smartTags"},{"id":114,"guid":"114.capabilities","index":9,"source":"capabilities"},{"id":131,"guid":"131.capabilities","index":10,"source":"capabilities"},{"id":105,"guid":"105.capabilities","index":11,"source":"capabilities"},{"id":1237,"guid":"1237.smart_tags","index":12,"source":"smartTags"},{"id":1188,"guid":"1188.smart_tags","index":13,"source":"smartTags"}],"is_active":true,"last_name":"Silbert","nick_name":"Elizabeth","clerkships":[],"first_name":"Elizabeth","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Leading Lawyer","detail":"Legal 500 US, 2025"},{"title":"Named as a Top 500 Leading Global Litigator Worldwide","detail":"LawDragon, 2023 - 2025"},{"title":"Listed in GAR’s 45 Under 45 Worldwide Survey for Leaders in International Arbitration","detail":"Global Arbitration Review, 2023"},{"title":"Recommended as a “talented” Next Generation Partner","detail":"Legal 500 US, 2022-2023"},{"title":"Recommended","detail":"Legal 500 US, 2020"},{"title":"Rising Star in International Arbitration","detail":"Law360, 2018"}],"linked_in_url":"https://www.linkedin.com/in/elizabeth-silbert-b668a637/","seodescription":"Elizabeth is the Co-Head of the firm's International Disputes Practice Group. Read more about her.","primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eElizabeth is the Co-Head of the firm's International Disputes Practice Group.\u0026nbsp; With particular knowledge of\u0026nbsp;the\u0026nbsp;energy, tech, and pharma industries, Elizabeth represents clients in high-profile disputes involving major\u0026nbsp;projects and long-term foreign investments.\u0026nbsp; Her cases are regularly at the cutting edge of international arbitration practice, and several exceed USD 1 billion in dispute.\u0026nbsp; Elizabeth is licensed to practice in New York, Georgia, and Texas, and has repeated experience in disputes involving the governing laws of the U.S., England, and various jurisdictions in Europe and Asia.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eElizabeth solves cross-border problems for her clients, having represented\u0026nbsp;clients in dozens of investor-State and commercial arbitrations and disputes.\u0026nbsp; She specializes in complex cases involving multiple parties,\u0026nbsp;government\u0026nbsp;entities, and cross-jurisdictional aspects.\u0026nbsp; Her counsel experience includes arbitrations convened under the AAA/ICDR, CPR, ICC, ICSID, LCIA, SIAC, and UNCITRAL Arbitration Rules, and practice in U.S. federal courts.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eElizabeth is particularly familiar with the legal and technical aspects of disputes in the energy, tech, and pharma industries.\u0026nbsp; She has handled numerous cases arising from long-term contracts (sale and purchase, supply, production sharing, concession,\u0026nbsp;EPC, licensing, etc.), deepening her knowledge not only of the contractual frameworks but also the practical and logistical\u0026nbsp;aspects of long-term investment projects.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eShe has experience coordinating parallel proceedings in \"viral\" disputes, including cross-border litigations, Section 1782 discovery, commercial and treaty arbitrations, and injunction and enforcement proceedings.\u0026nbsp; She also has significant experience representing major investors in treaty-based claims against States, and she regularly provides pre-dispute advice on foreign investment protection\u0026nbsp;and treaty analysis.\u003c/p\u003e\n\u003cp\u003eAlong with other accolades for her advocacy and client service, Global Arbitration Review selected Elizabeth for their\u0026nbsp;\"45 under 45\" global survey, and\u0026nbsp;Legal 500 named her a\u0026nbsp;\"Leading Lawyer\" in 2025.\u0026nbsp; In addition to her practice and frequent contributions as a speaker and author, Elizabeth acts as an Adjunct Law Professor at Emory University School of Law.\u0026nbsp; She is also committed to youth development in her community, and currently\u0026nbsp;serves\u0026nbsp;on the Board of Directors for the Boys \u0026amp; Girls Club of Metro Atlanta.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003eThe Coca-Cola Company\u003c/strong\u003e\u0026nbsp;in a Europe-based commercial arbitration under a long-term sponsorship agreement.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eChevron Thailand Exploration \u0026amp; Production Co\u003c/strong\u003e. in an ad hoc arbitration against the Kingdom of Thailand and the Ministry of Energy of Thailand, concerning a dispute in excess of US$ 2 billion regarding the decommissioning of offshore assets in the Gulf of Thailand.\u003c/p\u003e","\u003cp\u003eObtained a declaratory award worth more than US$1 billion for a\u0026nbsp;\u003cstrong\u003emajor Asia-based power consortium\u003c/strong\u003e\u0026nbsp;in a SIAC arbitration seated in Singapore, concerning a contractual dispute in the power transmission industry.\u003c/p\u003e","\u003cp\u003eRepresenting a\u0026nbsp;\u003cstrong\u003eEuropean trading company\u003c/strong\u003e\u0026nbsp;in a commercial arbitration seated in New York, concerning US$ 500 million breach of contract claims under various corporate and shareholders' agreements in a South American joint venture.\u003c/p\u003e","\u003cp\u003eObtained a declaratory award worth more than US$ 600 million on behalf of a\u0026nbsp;\u003cstrong\u003emajor U.S. LNG company\u003c/strong\u003e\u0026nbsp;in a AAA arbitration seated in Houston, concerning various breach-of-contract claims.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003eChevron Corporation\u003c/strong\u003e\u0026nbsp;in a treaty arbitration against the Republic of Ecuador seated in The Hague, concerning the US$9 billion \"Lago Agrio\" environmental judgment issued by the Ecuadorian courts, resulting in precedent-setting awards in favor of Chevron, including a finding of denial of justice and treaty breaches by Ecuador's courts, as well as numerous interim measures awards ordering Ecuador to prevent enforcement of the court judgment.\u003c/p\u003e","\u003cp\u003eWon an award for declaratory relief worth over $4 billion in an ICC arbitration on behalf of\u0026nbsp;\u003cstrong\u003etwo international oil majors\u0026nbsp;\u003c/strong\u003eagainst a Southeast Asian government, arising out of a revenue-allocation dispute under a gas service contract.\u003c/p\u003e","\u003cp\u003eObtained a denial of Section 1782 discovery in aid of a foreign commercial arbitration on behalf of\u0026nbsp;\u003cstrong\u003eHalliburton Company\u0026nbsp;\u003c/strong\u003efrom the U.S. District Court of a Delaware, including affirmance on appeal before the Third Circuit.\u003c/p\u003e","\u003cp\u003eWon a US$ 158 million award on behalf of\u0026nbsp;\u003cstrong\u003eGE-Hitachi Nuclear Energy Americas LLC\u003c/strong\u003e\u0026nbsp;in an ICC arbitration against a national power company seated in Taiwan, involving contractual and technical claims related to the construction of a nuclear power plant.\u003c/p\u003e","\u003cp\u003eWon a US$ 85 million award on behalf of\u0026nbsp;\u003cstrong\u003ea major U.S. energy company\u003c/strong\u003e\u0026nbsp;in an UNCITRAL arbitration seated in London, concerning breach-of-contract claims related to a gas pipeline project in Indonesia.\u003c/p\u003e","\u003cp\u003eWon a declaratory award (with costs) worth approximately US$ 1.5 billion on behalf of\u0026nbsp;\u003cstrong\u003ea U.S. LNG company,\u0026nbsp;\u003c/strong\u003ein an ICDR arbitration seated in New York concerning the terms of a long-term tolling agreement.\u003c/p\u003e","\u003cp\u003eWon a US$ 96 million final award on behalf of\u0026nbsp;\u003cstrong\u003eChevron Corporation\u003c/strong\u003e\u0026nbsp;in an UNCITRAL arbitration against the Republic of Ecuador seated in The Hague related to undue delays by Ecuadorian courts, including assistance in successful defense against set-aside proceedings in The Netherlands through all levels of appeals.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eShell Philippines Exploration B.V\u003c/strong\u003e\u003cstrong\u003e.\u003c/strong\u003e\u0026nbsp;in a multi-billion-dollar ICSID arbitration against the Republic of the Philippines under the Netherlands-Philippines bilateral investment treaty concerning the mistreatment of Shell\u0026rsquo;s investment in the Malampaya gas-to-power project.\u003c/p\u003e","\u003cp\u003eObtained favorable settlement on behalf of\u0026nbsp;\u003cstrong\u003ea European technology company\u003c/strong\u003e\u0026nbsp;in an ICDR arbitration seated in London, concerning a software licensing dispute.\u003c/p\u003e"],"recognitions":[{"title":"Leading Lawyer","detail":"Legal 500 US, 2025"},{"title":"Named as a Top 500 Leading Global Litigator Worldwide","detail":"LawDragon, 2023 - 2025"},{"title":"Listed in GAR’s 45 Under 45 Worldwide Survey for Leaders in International Arbitration","detail":"Global Arbitration Review, 2023"},{"title":"Recommended as a “talented” Next Generation Partner","detail":"Legal 500 US, 2022-2023"},{"title":"Recommended","detail":"Legal 500 US, 2020"},{"title":"Rising Star in International Arbitration","detail":"Law360, 2018"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":5815}]},"capability_group_id":3},"created_at":"2025-12-05T20:00:26.000Z","updated_at":"2025-12-05T20:00:26.000Z","searchable_text":"Silbert{{ FIELD }}{:title=\u0026gt;\"Leading Lawyer\", :detail=\u0026gt;\"Legal 500 US, 2025\"}{{ FIELD }}{:title=\u0026gt;\"Named as a Top 500 Leading Global Litigator Worldwide\", :detail=\u0026gt;\"LawDragon, 2023 - 2025\"}{{ FIELD }}{:title=\u0026gt;\"Listed in GAR’s 45 Under 45 Worldwide Survey for Leaders in International Arbitration\", :detail=\u0026gt;\"Global Arbitration Review, 2023\"}{{ FIELD }}{:title=\u0026gt;\"Recommended as a “talented” Next Generation Partner\", :detail=\u0026gt;\"Legal 500 US, 2022-2023\"}{{ FIELD }}{:title=\u0026gt;\"Recommended\", :detail=\u0026gt;\"Legal 500 US, 2020\"}{{ FIELD }}{:title=\u0026gt;\"Rising Star in International Arbitration\", :detail=\u0026gt;\"Law360, 2018\"}{{ FIELD }}Representing The Coca-Cola Company in a Europe-based commercial arbitration under a long-term sponsorship agreement.{{ FIELD }}Represented Chevron Thailand Exploration \u0026amp; Production Co. in an ad hoc arbitration against the Kingdom of Thailand and the Ministry of Energy of Thailand, concerning a dispute in excess of US$ 2 billion regarding the decommissioning of offshore assets in the Gulf of Thailand.{{ FIELD }}Obtained a declaratory award worth more than US$1 billion for a major Asia-based power consortium in a SIAC arbitration seated in Singapore, concerning a contractual dispute in the power transmission industry.{{ FIELD }}Representing a European trading company in a commercial arbitration seated in New York, concerning US$ 500 million breach of contract claims under various corporate and shareholders' agreements in a South American joint venture.{{ FIELD }}Obtained a declaratory award worth more than US$ 600 million on behalf of a major U.S. LNG company in a AAA arbitration seated in Houston, concerning various breach-of-contract claims.{{ FIELD }}Representing Chevron Corporation in a treaty arbitration against the Republic of Ecuador seated in The Hague, concerning the US$9 billion \"Lago Agrio\" environmental judgment issued by the Ecuadorian courts, resulting in precedent-setting awards in favor of Chevron, including a finding of denial of justice and treaty breaches by Ecuador's courts, as well as numerous interim measures awards ordering Ecuador to prevent enforcement of the court judgment.{{ FIELD }}Won an award for declaratory relief worth over $4 billion in an ICC arbitration on behalf of two international oil majors against a Southeast Asian government, arising out of a revenue-allocation dispute under a gas service contract.{{ FIELD }}Obtained a denial of Section 1782 discovery in aid of a foreign commercial arbitration on behalf of Halliburton Company from the U.S. District Court of a Delaware, including affirmance on appeal before the Third Circuit.{{ FIELD }}Won a US$ 158 million award on behalf of GE-Hitachi Nuclear Energy Americas LLC in an ICC arbitration against a national power company seated in Taiwan, involving contractual and technical claims related to the construction of a nuclear power plant.{{ FIELD }}Won a US$ 85 million award on behalf of a major U.S. energy company in an UNCITRAL arbitration seated in London, concerning breach-of-contract claims related to a gas pipeline project in Indonesia.{{ FIELD }}Won a declaratory award (with costs) worth approximately US$ 1.5 billion on behalf of a U.S. LNG company, in an ICDR arbitration seated in New York concerning the terms of a long-term tolling agreement.{{ FIELD }}Won a US$ 96 million final award on behalf of Chevron Corporation in an UNCITRAL arbitration against the Republic of Ecuador seated in The Hague related to undue delays by Ecuadorian courts, including assistance in successful defense against set-aside proceedings in The Netherlands through all levels of appeals.{{ FIELD }}Represented Shell Philippines Exploration B.V. in a multi-billion-dollar ICSID arbitration against the Republic of the Philippines under the Netherlands-Philippines bilateral investment treaty concerning the mistreatment of Shell’s investment in the Malampaya gas-to-power project.{{ FIELD }}Obtained favorable settlement on behalf of a European technology company in an ICDR arbitration seated in London, concerning a software licensing dispute.{{ FIELD }}Elizabeth is the Co-Head of the firm's International Disputes Practice Group.  With particular knowledge of the energy, tech, and pharma industries, Elizabeth represents clients in high-profile disputes involving major projects and long-term foreign investments.  Her cases are regularly at the cutting edge of international arbitration practice, and several exceed USD 1 billion in dispute.  Elizabeth is licensed to practice in New York, Georgia, and Texas, and has repeated experience in disputes involving the governing laws of the U.S., England, and various jurisdictions in Europe and Asia. \nElizabeth solves cross-border problems for her clients, having represented clients in dozens of investor-State and commercial arbitrations and disputes.  She specializes in complex cases involving multiple parties, government entities, and cross-jurisdictional aspects.  Her counsel experience includes arbitrations convened under the AAA/ICDR, CPR, ICC, ICSID, LCIA, SIAC, and UNCITRAL Arbitration Rules, and practice in U.S. federal courts. \nElizabeth is particularly familiar with the legal and technical aspects of disputes in the energy, tech, and pharma industries.  She has handled numerous cases arising from long-term contracts (sale and purchase, supply, production sharing, concession, EPC, licensing, etc.), deepening her knowledge not only of the contractual frameworks but also the practical and logistical aspects of long-term investment projects. \nShe has experience coordinating parallel proceedings in \"viral\" disputes, including cross-border litigations, Section 1782 discovery, commercial and treaty arbitrations, and injunction and enforcement proceedings.  She also has significant experience representing major investors in treaty-based claims against States, and she regularly provides pre-dispute advice on foreign investment protection and treaty analysis.\nAlong with other accolades for her advocacy and client service, Global Arbitration Review selected Elizabeth for their \"45 under 45\" global survey, and Legal 500 named her a \"Leading Lawyer\" in 2025.  In addition to her practice and frequent contributions as a speaker and author, Elizabeth acts as an Adjunct Law Professor at Emory University School of Law.  She is also committed to youth development in her community, and currently serves on the Board of Directors for the Boys \u0026amp; Girls Club of Metro Atlanta.\n  Elizabeth Silbert lawyer Partner Leading Lawyer Legal 500 US, 2025 Named as a Top 500 Leading Global Litigator Worldwide LawDragon, 2023 - 2025 Listed in GAR’s 45 Under 45 Worldwide Survey for Leaders in International Arbitration Global Arbitration Review, 2023 Recommended as a “talented” Next Generation Partner Legal 500 US, 2022-2023 Recommended Legal 500 US, 2020 Rising Star in International Arbitration Law360, 2018 Georgetown University Georgetown University Law Center Northwestern University Northwestern Pritzker School of Law U.S. District Court for the Eastern District of Texas U.S. District Court for the Northern District of Georgia Georgia New York Texas Representing The Coca-Cola Company in a Europe-based commercial arbitration under a long-term sponsorship agreement. Represented Chevron Thailand Exploration \u0026amp; Production Co. in an ad hoc arbitration against the Kingdom of Thailand and the Ministry of Energy of Thailand, concerning a dispute in excess of US$ 2 billion regarding the decommissioning of offshore assets in the Gulf of Thailand. Obtained a declaratory award worth more than US$1 billion for a major Asia-based power consortium in a SIAC arbitration seated in Singapore, concerning a contractual dispute in the power transmission industry. Representing a European trading company in a commercial arbitration seated in New York, concerning US$ 500 million breach of contract claims under various corporate and shareholders' agreements in a South American joint venture. Obtained a declaratory award worth more than US$ 600 million on behalf of a major U.S. LNG company in a AAA arbitration seated in Houston, concerning various breach-of-contract claims. Representing Chevron Corporation in a treaty arbitration against the Republic of Ecuador seated in The Hague, concerning the US$9 billion \"Lago Agrio\" environmental judgment issued by the Ecuadorian courts, resulting in precedent-setting awards in favor of Chevron, including a finding of denial of justice and treaty breaches by Ecuador's courts, as well as numerous interim measures awards ordering Ecuador to prevent enforcement of the court judgment. Won an award for declaratory relief worth over $4 billion in an ICC arbitration on behalf of two international oil majors against a Southeast Asian government, arising out of a revenue-allocation dispute under a gas service contract. Obtained a denial of Section 1782 discovery in aid of a foreign commercial arbitration on behalf of Halliburton Company from the U.S. District Court of a Delaware, including affirmance on appeal before the Third Circuit. Won a US$ 158 million award on behalf of GE-Hitachi Nuclear Energy Americas LLC in an ICC arbitration against a national power company seated in Taiwan, involving contractual and technical claims related to the construction of a nuclear power plant. Won a US$ 85 million award on behalf of a major U.S. energy company in an UNCITRAL arbitration seated in London, concerning breach-of-contract claims related to a gas pipeline project in Indonesia. Won a declaratory award (with costs) worth approximately US$ 1.5 billion on behalf of a U.S. LNG company, in an ICDR arbitration seated in New York concerning the terms of a long-term tolling agreement. Won a US$ 96 million final award on behalf of Chevron Corporation in an UNCITRAL arbitration against the Republic of Ecuador seated in The Hague related to undue delays by Ecuadorian courts, including assistance in successful defense against set-aside proceedings in The Netherlands through all levels of appeals. Represented Shell Philippines Exploration B.V. in a multi-billion-dollar ICSID arbitration against the Republic of the Philippines under the Netherlands-Philippines bilateral investment treaty concerning the mistreatment of Shell’s investment in the Malampaya gas-to-power project. Obtained favorable settlement on behalf of a European technology company in an ICDR arbitration seated in London, concerning a software licensing dispute.","searchable_name":"Elizabeth Silbert","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":442766,"version":1,"owner_type":"Person","owner_id":5387,"payload":{"bio":"\u003cp\u003eAs a data, privacy and security, health care, and employee benefits partner at King \u0026amp; Spalding LLP, Adam Solander provides counsel on data breach and cybersecurity issues across various industries, particularly health care. Adam represents clients with respect to employee benefits regulatory and compliance issues including designing, implementing, and maintaining employee benefit plans. He also advises clients on issues related to managed care laws and telemedicine.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAdam has experience helping clients preparing for, responding to, and recovering from data, privacy and security incidents. He is a Certified CSF Practitioner, a designation given by the Health Information Trust Alliance (HITRUST). This organization provides training to develop and maintain effective security programs for health care and life sciences companies that comply with security laws, regulations, and standards, including HITECH, HIPAA, PCI, JCAHO, CMS, ISO, NIST, and various other federal, state, and business requirements.\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Adam was a member of a nationally recognized law firm where he was a part of their health care and life sciences practice group. Much of his experience is centered around assisting health care clients with HIPAA compliance, ERISA, managed care laws, telemedicine, and privacy and data security. \u0026nbsp;He also assisted private equity companies with evaluating privacy and security and employee benefits compliance risk in connection with potential investments.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePreviously, he served as Health Policy Counsel at the ERISA Industry Committee. There, he counseled Fortune 500 companies on healthcare legislation, including ACA, the HITECH Act, and ERISA. He also has experience advocating on behalf of trade associations and advocacy groups to Congress and Executive branch.\u003c/p\u003e","slug":"adam-solander","email":"asolander@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":6,"guid":"6.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":28,"guid":"28.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":80,"guid":"80.capabilities","index":5,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":6,"source":"smartTags"}],"is_active":true,"last_name":"Solander","nick_name":"Adam","clerkships":[],"first_name":"Adam","title_rank":9999,"updated_by":101,"law_schools":[{"id":1562,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"2007-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"C.","name_suffix":"","recognitions":[{"title":"Named to Washington DC Rising Stars list","detail":"Super Lawyers, 2016-2018"},{"title":"Received Readers’ Choice Award","detail":"JD Supra, 2016"},{"title":"Received Burton Award for Legal Writing","detail":"Burton Awards Program in association with the Library of Congress, 2014"}],"linked_in_url":"https://www.linkedin.com/in/adamsolander/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAs a data, privacy and security, health care, and employee benefits partner at King \u0026amp; Spalding LLP, Adam Solander provides counsel on data breach and cybersecurity issues across various industries, particularly health care. Adam represents clients with respect to employee benefits regulatory and compliance issues including designing, implementing, and maintaining employee benefit plans. He also advises clients on issues related to managed care laws and telemedicine.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAdam has experience helping clients preparing for, responding to, and recovering from data, privacy and security incidents. He is a Certified CSF Practitioner, a designation given by the Health Information Trust Alliance (HITRUST). This organization provides training to develop and maintain effective security programs for health care and life sciences companies that comply with security laws, regulations, and standards, including HITECH, HIPAA, PCI, JCAHO, CMS, ISO, NIST, and various other federal, state, and business requirements.\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Adam was a member of a nationally recognized law firm where he was a part of their health care and life sciences practice group. Much of his experience is centered around assisting health care clients with HIPAA compliance, ERISA, managed care laws, telemedicine, and privacy and data security. \u0026nbsp;He also assisted private equity companies with evaluating privacy and security and employee benefits compliance risk in connection with potential investments.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePreviously, he served as Health Policy Counsel at the ERISA Industry Committee. There, he counseled Fortune 500 companies on healthcare legislation, including ACA, the HITECH Act, and ERISA. He also has experience advocating on behalf of trade associations and advocacy groups to Congress and Executive branch.\u003c/p\u003e","recognitions":[{"title":"Named to Washington DC Rising Stars list","detail":"Super Lawyers, 2016-2018"},{"title":"Received Readers’ Choice Award","detail":"JD Supra, 2016"},{"title":"Received Burton Award for Legal Writing","detail":"Burton Awards Program in association with the Library of Congress, 2014"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6393}]},"capability_group_id":2},"created_at":"2025-11-13T04:56:44.000Z","updated_at":"2025-11-13T04:56:44.000Z","searchable_text":"Solander{{ FIELD }}{:title=\u0026gt;\"Named to Washington DC Rising Stars list\", :detail=\u0026gt;\"Super Lawyers, 2016-2018\"}{{ FIELD }}{:title=\u0026gt;\"Received Readers’ Choice Award\", :detail=\u0026gt;\"JD Supra, 2016\"}{{ FIELD }}{:title=\u0026gt;\"Received Burton Award for Legal Writing\", :detail=\u0026gt;\"Burton Awards Program in association with the Library of Congress, 2014\"}{{ FIELD }}As a data, privacy and security, health care, and employee benefits partner at King \u0026amp; Spalding LLP, Adam Solander provides counsel on data breach and cybersecurity issues across various industries, particularly health care. Adam represents clients with respect to employee benefits regulatory and compliance issues including designing, implementing, and maintaining employee benefit plans. He also advises clients on issues related to managed care laws and telemedicine.\nAdam has experience helping clients preparing for, responding to, and recovering from data, privacy and security incidents. He is a Certified CSF Practitioner, a designation given by the Health Information Trust Alliance (HITRUST). This organization provides training to develop and maintain effective security programs for health care and life sciences companies that comply with security laws, regulations, and standards, including HITECH, HIPAA, PCI, JCAHO, CMS, ISO, NIST, and various other federal, state, and business requirements.\nPrior to joining King \u0026amp; Spalding, Adam was a member of a nationally recognized law firm where he was a part of their health care and life sciences practice group. Much of his experience is centered around assisting health care clients with HIPAA compliance, ERISA, managed care laws, telemedicine, and privacy and data security.  He also assisted private equity companies with evaluating privacy and security and employee benefits compliance risk in connection with potential investments. \nPreviously, he served as Health Policy Counsel at the ERISA Industry Committee. There, he counseled Fortune 500 companies on healthcare legislation, including ACA, the HITECH Act, and ERISA. He also has experience advocating on behalf of trade associations and advocacy groups to Congress and Executive branch. Partner Named to Washington DC Rising Stars list Super Lawyers, 2016-2018 Received Readers’ Choice Award JD Supra, 2016 Received Burton Award for Legal Writing Burton Awards Program in association with the Library of Congress, 2014 West Virginia University West Virginia University College of Law Pennsylvania State University Pennsylvania State University, Dickinson School of Law West Virginia University West Virginia University College of Law District of Columbia District of Columbia Bar Association Member, American Health Lawyers Association","searchable_name":"Adam C. Solander","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":442769,"version":1,"owner_type":"Person","owner_id":5404,"payload":{"bio":"\u003cdiv id=\"pnlProfileSummaryShort\"\u003e\n\u003cp\u003eGlenn Solomon specializes in commercial and government managed care, complex business litigation, arbitration, mediation, class action, investigations, and other dispute resolution matters. As a partner in our Healthcare practice, his diverse clientele includes prominent hospitals and health systems, medical groups, independent physician associations, management services organizations, and other health care providers and entities. On behalf of providers, he has both resolved significant disputes with health plans and negotiated high-profile contracts with them, as well as solved disagreements with other providers.\u0026nbsp; He has helped providers obtain several hundred million\u0026nbsp;dollars through underpayments recoveries, contract improvements, and negotiations.\u0026nbsp; He also has successfully defended against similarly large amounts of alleged overpayments.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGlenn\u0026rsquo;s expertise allows him to break down complex disputes to identify and achieve the best options for his clients, whether that be through litigation, arbitration, mediation, or resolved through contractual negotiation. His clients have recovered combined awards and settlements totaling over several hundred million dollars on the plaintiffs\u0026rsquo; side; and have successfully avoided alleged financial exposures of similar figures on the defendants\u0026rsquo; side.\u003c/p\u003e\n\u003cp\u003eOver the course of his career, Glenn has litigated, arbitrated, mediated and resolved disputes involving managed care, contracting, management services, class actions, internal and external investigations, fraud and abuse, business relations, reimbursement, trade secrets, misappropriation, real estate, employment, and discrimination. His broad health industry experience involves dealings with health plans, insurance companies, ERISA plans, self-funded plans, qui tam relators, employees, other providers and the government. Glenn\u0026rsquo;s versatile background has allowed him to be a court-designated expert witness.\u003c/p\u003e\n\u003cp\u003eGlenn also has experience representing clients in other industries such as telecommunications, accounting, retail, and banking.\u003c/p\u003e\n\u003cp\u003eGlenn is also recognized by Legal 500 (2024) as a Key Lawyer in HealthCare: Service Providers, which group has been ranked Tier 1 for this industry.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGlenn continues to be recognized by Legal 500 (2025) as a Key Lawyer in HealthCare: Service Providers.\u003c/p\u003e\n\u003cp\u003eGlenn also has been recognized by Chambers USA, LA Attorney Individual Ranking for Healthcare.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGlenn has been selected for the Los Angeles Business Journal's 2025 Leaders of Influence: Litigators \u0026amp; Trial Attorneys.\u003c/p\u003e\n\u003c/div\u003e","slug":"glenn-solomon","email":"gsolomon@kslaw.com","phone":null,"matters":["\u003cp\u003eRepresented\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003cstrong\u003eCalifornia Hospital Association\u003c/strong\u003e,\u0026nbsp;\u003cstrong\u003eCalifornia Medical Association\u003c/strong\u003e,\u0026nbsp;\u003cstrong\u003eRegional Medical Center of San Jose, and Good Samaritan Hospital\u003c/strong\u003e\u0026nbsp;as amici in\u0026nbsp;\u003cem\u003eCounty of Santa Clara v. Sup. Ct.\u003c/em\u003e, 14 Cal.5th 1034 (2023), in which the California Supreme Court, reversing a lower court decision, held that government owned health plans are subject to the Knox-Keene Act and lawsuits for reimbursement by out-of-network providers; potential impact exceeds hundreds of millions of dollars for California out-of-network providers.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCEP America California dba Vituity\u003c/strong\u003e\u0026nbsp;against Heritage Provider Network regarding underpayments for out-of-network emergency physician services at many hospitals, resulting in jury award in April 2023, against the health plan on claims exceeding $10 million.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCalifornia Hospital Association\u003c/strong\u003e,\u0026nbsp;\u003cstrong\u003eCalifornia Medical Association\u003c/strong\u003e, and a plaintiff class of\u0026nbsp;\u003cstrong\u003eCalifornia hospitals\u003c/strong\u003e\u0026nbsp;against Blue Cross regarding post-claims underwriting; court-approved settlement pool of $11.8 million for the benefit of all California hospitals that were affected by Blue Cross\u0026rsquo;s rescissions of patient policies.\u003c/p\u003e","\u003cp\u003eRepresented plaintiff's class of California \u003cstrong\u003eAmbulatory Surgery Centers\u0026nbsp;\u003c/strong\u003eagainst United Healthcare, Ingenix (now Optum) and dozens of self-funded plans regarding out-of-network payments; class settlement reached for $9.5 million for the benefit of California ASCs.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eChildren's Hospital Central California\u003c/strong\u003e\u0026nbsp;against Blue Cross of California in which appeals court held that the parties can present to the jury ona variety of evidence, includingthe hospital's charges, contracted rates and government rates, but not the costs to render the services at issue.\u003c/p\u003e","\u003cp\u003eJury verdict for\u0026nbsp;\u003cstrong\u003eChildren's Hospital Central California\u0026nbsp;\u003c/strong\u003edetermining plan was liable at 100% of charges for post-stabilization services rendered by hospital when plan failed to transfer Medi-Cal managed care beneficiaries to alternative providers; jury rejected plan's argument that hospital had not received authorization or been deemed authored.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCalifornia Hospital Association\u003c/strong\u003e, plus a national dialysis provider and a putative class of ambulatory surgery centers nationwide, in obtaining court order that national class action settlement agreement regarding United\u0026rsquo;s reimbursement practices to non-contracted physicians doesn\u0026rsquo;t bar facilities from pursuing underpayment claims for facility services.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eC/HCA, Inc.\u003c/strong\u003e\u0026nbsp;in federal court to obtain preliminary injunction against Regence Blue Cross Blue Shield of Utah from marketing the hospitals as being in-network providers for new tiered network product that was not contemplated by the parties\u0026rsquo; contract.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCoast Plaza Doctors Hosp.\u003c/strong\u003e\u0026nbsp;against an Anthem Blue plan in appeals court decision that providers aren\u0026rsquo;t preempted from pursuing direct state law claims against non-self-funded ERISA health plans and can sue such plans, rather than as assignees of the patient\u0026rsquo;s ERISA benefits.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eMount Diablo Medical Center\u003c/strong\u003e\u0026nbsp;in successful defeat of Health Net of California's motion to compel arbitration where dispute also involved the health plan's entity who was not subject to arbitration in multiparty capitation network dispute.\u003c/p\u003e","\u003cp\u003eRepresented prominent\u0026nbsp;\u003cstrong\u003epsychiatric hospitals\u0026nbsp;\u003c/strong\u003ein complex negotiations with the city of Los Angeles for a pre-filing settlement and stipulated judgment to resolve allegations of improper psychiatric patient discharges and then develop patient safety standards with the city for wider use as part of a year-long collaborative task force.\u003c/p\u003e","\u003cp\u003eRepresented a number of prominent non-profit hospitals in\u0026nbsp;\u003cstrong\u003eclass action defense\u0026nbsp;\u003c/strong\u003eagainst uninsured patients challenging various charges and billing practices.\u003c/p\u003e","\u003cp\u003eIn addition to these and other public court matters, Mr. Solomon often resolves matters outside the court system, through settlement negotiations, mediations and arbitrations for providers throughout the country. Over the course of his career he has worked on matters collectively generating\u0026nbsp;\u003cstrong\u003eseveral hundred million dollars\u0026nbsp;\u003c/strong\u003efor his provider clients in additional revenue from underpayments and avoided recoupment of similar amounts in alleged overpayments.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":1,"source":"capabilities"},{"id":3,"guid":"3.capabilities","index":2,"source":"capabilities"},{"id":12,"guid":"12.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":5,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":6,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":7,"source":"capabilities"},{"id":740,"guid":"740.smart_tags","index":8,"source":"smartTags"},{"id":122,"guid":"122.capabilities","index":9,"source":"capabilities"},{"id":1185,"guid":"1185.smart_tags","index":10,"source":"smartTags"},{"id":1187,"guid":"1187.smart_tags","index":11,"source":"smartTags"}],"is_active":true,"last_name":"Solomon","nick_name":"Glenn","clerkships":[],"first_name":"Glenn","title_rank":9999,"updated_by":34,"law_schools":[{"id":824,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"1991-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Key Lawyer in HealthCare: Service Providers","detail":"Legal 500, 2024"},{"title":"Martindale-Hubbell","detail":"AV Rated"},{"title":"Southern California Super Lawyers","detail":"2013-2020"},{"title":"Best Lawyers in America","detail":"2013-2020"}],"linked_in_url":"https://www.linkedin.com/in/glenn-solomon-1188b52/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cdiv id=\"pnlProfileSummaryShort\"\u003e\n\u003cp\u003eGlenn Solomon specializes in commercial and government managed care, complex business litigation, arbitration, mediation, class action, investigations, and other dispute resolution matters. As a partner in our Healthcare practice, his diverse clientele includes prominent hospitals and health systems, medical groups, independent physician associations, management services organizations, and other health care providers and entities. On behalf of providers, he has both resolved significant disputes with health plans and negotiated high-profile contracts with them, as well as solved disagreements with other providers.\u0026nbsp; He has helped providers obtain several hundred million\u0026nbsp;dollars through underpayments recoveries, contract improvements, and negotiations.\u0026nbsp; He also has successfully defended against similarly large amounts of alleged overpayments.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGlenn\u0026rsquo;s expertise allows him to break down complex disputes to identify and achieve the best options for his clients, whether that be through litigation, arbitration, mediation, or resolved through contractual negotiation. His clients have recovered combined awards and settlements totaling over several hundred million dollars on the plaintiffs\u0026rsquo; side; and have successfully avoided alleged financial exposures of similar figures on the defendants\u0026rsquo; side.\u003c/p\u003e\n\u003cp\u003eOver the course of his career, Glenn has litigated, arbitrated, mediated and resolved disputes involving managed care, contracting, management services, class actions, internal and external investigations, fraud and abuse, business relations, reimbursement, trade secrets, misappropriation, real estate, employment, and discrimination. His broad health industry experience involves dealings with health plans, insurance companies, ERISA plans, self-funded plans, qui tam relators, employees, other providers and the government. Glenn\u0026rsquo;s versatile background has allowed him to be a court-designated expert witness.\u003c/p\u003e\n\u003cp\u003eGlenn also has experience representing clients in other industries such as telecommunications, accounting, retail, and banking.\u003c/p\u003e\n\u003cp\u003eGlenn is also recognized by Legal 500 (2024) as a Key Lawyer in HealthCare: Service Providers, which group has been ranked Tier 1 for this industry.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGlenn continues to be recognized by Legal 500 (2025) as a Key Lawyer in HealthCare: Service Providers.\u003c/p\u003e\n\u003cp\u003eGlenn also has been recognized by Chambers USA, LA Attorney Individual Ranking for Healthcare.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGlenn has been selected for the Los Angeles Business Journal's 2025 Leaders of Influence: Litigators \u0026amp; Trial Attorneys.\u003c/p\u003e\n\u003c/div\u003e","matters":["\u003cp\u003eRepresented\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003cstrong\u003eCalifornia Hospital Association\u003c/strong\u003e,\u0026nbsp;\u003cstrong\u003eCalifornia Medical Association\u003c/strong\u003e,\u0026nbsp;\u003cstrong\u003eRegional Medical Center of San Jose, and Good Samaritan Hospital\u003c/strong\u003e\u0026nbsp;as amici in\u0026nbsp;\u003cem\u003eCounty of Santa Clara v. Sup. Ct.\u003c/em\u003e, 14 Cal.5th 1034 (2023), in which the California Supreme Court, reversing a lower court decision, held that government owned health plans are subject to the Knox-Keene Act and lawsuits for reimbursement by out-of-network providers; potential impact exceeds hundreds of millions of dollars for California out-of-network providers.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCEP America California dba Vituity\u003c/strong\u003e\u0026nbsp;against Heritage Provider Network regarding underpayments for out-of-network emergency physician services at many hospitals, resulting in jury award in April 2023, against the health plan on claims exceeding $10 million.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCalifornia Hospital Association\u003c/strong\u003e,\u0026nbsp;\u003cstrong\u003eCalifornia Medical Association\u003c/strong\u003e, and a plaintiff class of\u0026nbsp;\u003cstrong\u003eCalifornia hospitals\u003c/strong\u003e\u0026nbsp;against Blue Cross regarding post-claims underwriting; court-approved settlement pool of $11.8 million for the benefit of all California hospitals that were affected by Blue Cross\u0026rsquo;s rescissions of patient policies.\u003c/p\u003e","\u003cp\u003eRepresented plaintiff's class of California \u003cstrong\u003eAmbulatory Surgery Centers\u0026nbsp;\u003c/strong\u003eagainst United Healthcare, Ingenix (now Optum) and dozens of self-funded plans regarding out-of-network payments; class settlement reached for $9.5 million for the benefit of California ASCs.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eChildren's Hospital Central California\u003c/strong\u003e\u0026nbsp;against Blue Cross of California in which appeals court held that the parties can present to the jury ona variety of evidence, includingthe hospital's charges, contracted rates and government rates, but not the costs to render the services at issue.\u003c/p\u003e","\u003cp\u003eJury verdict for\u0026nbsp;\u003cstrong\u003eChildren's Hospital Central California\u0026nbsp;\u003c/strong\u003edetermining plan was liable at 100% of charges for post-stabilization services rendered by hospital when plan failed to transfer Medi-Cal managed care beneficiaries to alternative providers; jury rejected plan's argument that hospital had not received authorization or been deemed authored.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCalifornia Hospital Association\u003c/strong\u003e, plus a national dialysis provider and a putative class of ambulatory surgery centers nationwide, in obtaining court order that national class action settlement agreement regarding United\u0026rsquo;s reimbursement practices to non-contracted physicians doesn\u0026rsquo;t bar facilities from pursuing underpayment claims for facility services.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eC/HCA, Inc.\u003c/strong\u003e\u0026nbsp;in federal court to obtain preliminary injunction against Regence Blue Cross Blue Shield of Utah from marketing the hospitals as being in-network providers for new tiered network product that was not contemplated by the parties\u0026rsquo; contract.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eCoast Plaza Doctors Hosp.\u003c/strong\u003e\u0026nbsp;against an Anthem Blue plan in appeals court decision that providers aren\u0026rsquo;t preempted from pursuing direct state law claims against non-self-funded ERISA health plans and can sue such plans, rather than as assignees of the patient\u0026rsquo;s ERISA benefits.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eMount Diablo Medical Center\u003c/strong\u003e\u0026nbsp;in successful defeat of Health Net of California's motion to compel arbitration where dispute also involved the health plan's entity who was not subject to arbitration in multiparty capitation network dispute.\u003c/p\u003e","\u003cp\u003eRepresented prominent\u0026nbsp;\u003cstrong\u003epsychiatric hospitals\u0026nbsp;\u003c/strong\u003ein complex negotiations with the city of Los Angeles for a pre-filing settlement and stipulated judgment to resolve allegations of improper psychiatric patient discharges and then develop patient safety standards with the city for wider use as part of a year-long collaborative task force.\u003c/p\u003e","\u003cp\u003eRepresented a number of prominent non-profit hospitals in\u0026nbsp;\u003cstrong\u003eclass action defense\u0026nbsp;\u003c/strong\u003eagainst uninsured patients challenging various charges and billing practices.\u003c/p\u003e","\u003cp\u003eIn addition to these and other public court matters, Mr. Solomon often resolves matters outside the court system, through settlement negotiations, mediations and arbitrations for providers throughout the country. Over the course of his career he has worked on matters collectively generating\u0026nbsp;\u003cstrong\u003eseveral hundred million dollars\u0026nbsp;\u003c/strong\u003efor his provider clients in additional revenue from underpayments and avoided recoupment of similar amounts in alleged overpayments.\u003c/p\u003e"],"recognitions":[{"title":"Key Lawyer in HealthCare: Service Providers","detail":"Legal 500, 2024"},{"title":"Martindale-Hubbell","detail":"AV Rated"},{"title":"Southern California Super Lawyers","detail":"2013-2020"},{"title":"Best Lawyers in America","detail":"2013-2020"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6579}]},"capability_group_id":2},"created_at":"2025-11-13T04:56:47.000Z","updated_at":"2025-11-13T04:56:47.000Z","searchable_text":"Solomon{{ FIELD }}{:title=\u0026gt;\"Key Lawyer in HealthCare: Service Providers\", :detail=\u0026gt;\"Legal 500, 2024\"}{{ FIELD }}{:title=\u0026gt;\"Martindale-Hubbell\", :detail=\u0026gt;\"AV Rated\"}{{ FIELD }}{:title=\u0026gt;\"Southern California Super Lawyers\", :detail=\u0026gt;\"2013-2020\"}{{ FIELD }}{:title=\u0026gt;\"Best Lawyers in America\", :detail=\u0026gt;\"2013-2020\"}{{ FIELD }}Represented California Hospital Association, California Medical Association, Regional Medical Center of San Jose, and Good Samaritan Hospital as amici in County of Santa Clara v. Sup. Ct., 14 Cal.5th 1034 (2023), in which the California Supreme Court, reversing a lower court decision, held that government owned health plans are subject to the Knox-Keene Act and lawsuits for reimbursement by out-of-network providers; potential impact exceeds hundreds of millions of dollars for California out-of-network providers.{{ FIELD }}Represented CEP America California dba Vituity against Heritage Provider Network regarding underpayments for out-of-network emergency physician services at many hospitals, resulting in jury award in April 2023, against the health plan on claims exceeding $10 million.{{ FIELD }}Represented California Hospital Association, California Medical Association, and a plaintiff class of California hospitals against Blue Cross regarding post-claims underwriting; court-approved settlement pool of $11.8 million for the benefit of all California hospitals that were affected by Blue Cross’s rescissions of patient policies.{{ FIELD }}Represented plaintiff's class of California Ambulatory Surgery Centers against United Healthcare, Ingenix (now Optum) and dozens of self-funded plans regarding out-of-network payments; class settlement reached for $9.5 million for the benefit of California ASCs.{{ FIELD }}Represented Children's Hospital Central California against Blue Cross of California in which appeals court held that the parties can present to the jury ona variety of evidence, includingthe hospital's charges, contracted rates and government rates, but not the costs to render the services at issue.{{ FIELD }}Jury verdict for Children's Hospital Central California determining plan was liable at 100% of charges for post-stabilization services rendered by hospital when plan failed to transfer Medi-Cal managed care beneficiaries to alternative providers; jury rejected plan's argument that hospital had not received authorization or been deemed authored.{{ FIELD }}Represented California Hospital Association, plus a national dialysis provider and a putative class of ambulatory surgery centers nationwide, in obtaining court order that national class action settlement agreement regarding United’s reimbursement practices to non-contracted physicians doesn’t bar facilities from pursuing underpayment claims for facility services.{{ FIELD }}Represented C/HCA, Inc. in federal court to obtain preliminary injunction against Regence Blue Cross Blue Shield of Utah from marketing the hospitals as being in-network providers for new tiered network product that was not contemplated by the parties’ contract.{{ FIELD }}Represented Coast Plaza Doctors Hosp. against an Anthem Blue plan in appeals court decision that providers aren’t preempted from pursuing direct state law claims against non-self-funded ERISA health plans and can sue such plans, rather than as assignees of the patient’s ERISA benefits.{{ FIELD }}Represented Mount Diablo Medical Center in successful defeat of Health Net of California's motion to compel arbitration where dispute also involved the health plan's entity who was not subject to arbitration in multiparty capitation network dispute.{{ FIELD }}Represented prominent psychiatric hospitals in complex negotiations with the city of Los Angeles for a pre-filing settlement and stipulated judgment to resolve allegations of improper psychiatric patient discharges and then develop patient safety standards with the city for wider use as part of a year-long collaborative task force.{{ FIELD }}Represented a number of prominent non-profit hospitals in class action defense against uninsured patients challenging various charges and billing practices.{{ FIELD }}In addition to these and other public court matters, Mr. Solomon often resolves matters outside the court system, through settlement negotiations, mediations and arbitrations for providers throughout the country. Over the course of his career he has worked on matters collectively generating several hundred million dollars for his provider clients in additional revenue from underpayments and avoided recoupment of similar amounts in alleged overpayments.{{ FIELD }}\nGlenn Solomon specializes in commercial and government managed care, complex business litigation, arbitration, mediation, class action, investigations, and other dispute resolution matters. As a partner in our Healthcare practice, his diverse clientele includes prominent hospitals and health systems, medical groups, independent physician associations, management services organizations, and other health care providers and entities. On behalf of providers, he has both resolved significant disputes with health plans and negotiated high-profile contracts with them, as well as solved disagreements with other providers.  He has helped providers obtain several hundred million dollars through underpayments recoveries, contract improvements, and negotiations.  He also has successfully defended against similarly large amounts of alleged overpayments. \nGlenn’s expertise allows him to break down complex disputes to identify and achieve the best options for his clients, whether that be through litigation, arbitration, mediation, or resolved through contractual negotiation. His clients have recovered combined awards and settlements totaling over several hundred million dollars on the plaintiffs’ side; and have successfully avoided alleged financial exposures of similar figures on the defendants’ side.\nOver the course of his career, Glenn has litigated, arbitrated, mediated and resolved disputes involving managed care, contracting, management services, class actions, internal and external investigations, fraud and abuse, business relations, reimbursement, trade secrets, misappropriation, real estate, employment, and discrimination. His broad health industry experience involves dealings with health plans, insurance companies, ERISA plans, self-funded plans, qui tam relators, employees, other providers and the government. Glenn’s versatile background has allowed him to be a court-designated expert witness.\nGlenn also has experience representing clients in other industries such as telecommunications, accounting, retail, and banking.\nGlenn is also recognized by Legal 500 (2024) as a Key Lawyer in HealthCare: Service Providers, which group has been ranked Tier 1 for this industry. \nGlenn continues to be recognized by Legal 500 (2025) as a Key Lawyer in HealthCare: Service Providers.\nGlenn also has been recognized by Chambers USA, LA Attorney Individual Ranking for Healthcare. \nGlenn has been selected for the Los Angeles Business Journal's 2025 Leaders of Influence: Litigators \u0026amp; Trial Attorneys.\n Partner Key Lawyer in HealthCare: Service Providers Legal 500, 2024 Martindale-Hubbell AV Rated Southern California Super Lawyers 2013-2020 Best Lawyers in America 2013-2020 University of California, Berkeley University of California, Berkeley, School of Law Harvard University Harvard Law School U.S. Court of Appeals for the Ninth Circuit U.S. District Court for the Central District of California U.S. District Court for the Eastern District of California U.S. District Court for the Northern District of California U.S. District Court for the Southern District of California California Texas American Health Lawyers Association Healthcare Financial Management Association California Society of Healthcare Attorneys American Bar Association, Health Law and Litigation Sections California Bar Association, Litigation Section Los Angeles County Bar Association, Health Care and Litigation Sections Cedars-Sinai Medical Center, Board of Governors, Executive Committee The Maple Counseling Center, Board of Directors, Executive-Finance-Budget Committees Represented California Hospital Association, California Medical Association, Regional Medical Center of San Jose, and Good Samaritan Hospital as amici in County of Santa Clara v. Sup. Ct., 14 Cal.5th 1034 (2023), in which the California Supreme Court, reversing a lower court decision, held that government owned health plans are subject to the Knox-Keene Act and lawsuits for reimbursement by out-of-network providers; potential impact exceeds hundreds of millions of dollars for California out-of-network providers. Represented CEP America California dba Vituity against Heritage Provider Network regarding underpayments for out-of-network emergency physician services at many hospitals, resulting in jury award in April 2023, against the health plan on claims exceeding $10 million. Represented California Hospital Association, California Medical Association, and a plaintiff class of California hospitals against Blue Cross regarding post-claims underwriting; court-approved settlement pool of $11.8 million for the benefit of all California hospitals that were affected by Blue Cross’s rescissions of patient policies. Represented plaintiff's class of California Ambulatory Surgery Centers against United Healthcare, Ingenix (now Optum) and dozens of self-funded plans regarding out-of-network payments; class settlement reached for $9.5 million for the benefit of California ASCs. Represented Children's Hospital Central California against Blue Cross of California in which appeals court held that the parties can present to the jury ona variety of evidence, includingthe hospital's charges, contracted rates and government rates, but not the costs to render the services at issue. Jury verdict for Children's Hospital Central California determining plan was liable at 100% of charges for post-stabilization services rendered by hospital when plan failed to transfer Medi-Cal managed care beneficiaries to alternative providers; jury rejected plan's argument that hospital had not received authorization or been deemed authored. Represented California Hospital Association, plus a national dialysis provider and a putative class of ambulatory surgery centers nationwide, in obtaining court order that national class action settlement agreement regarding United’s reimbursement practices to non-contracted physicians doesn’t bar facilities from pursuing underpayment claims for facility services. Represented C/HCA, Inc. in federal court to obtain preliminary injunction against Regence Blue Cross Blue Shield of Utah from marketing the hospitals as being in-network providers for new tiered network product that was not contemplated by the parties’ contract. Represented Coast Plaza Doctors Hosp. against an Anthem Blue plan in appeals court decision that providers aren’t preempted from pursuing direct state law claims against non-self-funded ERISA health plans and can sue such plans, rather than as assignees of the patient’s ERISA benefits. Represented Mount Diablo Medical Center in successful defeat of Health Net of California's motion to compel arbitration where dispute also involved the health plan's entity who was not subject to arbitration in multiparty capitation network dispute. Represented prominent psychiatric hospitals in complex negotiations with the city of Los Angeles for a pre-filing settlement and stipulated judgment to resolve allegations of improper psychiatric patient discharges and then develop patient safety standards with the city for wider use as part of a year-long collaborative task force. Represented a number of prominent non-profit hospitals in class action defense against uninsured patients challenging various charges and billing practices. In addition to these and other public court matters, Mr. Solomon often resolves matters outside the court system, through settlement negotiations, mediations and arbitrations for providers throughout the country. Over the course of his career he has worked on matters collectively generating several hundred million dollars for his provider clients in additional revenue from underpayments and avoided recoupment of similar amounts in alleged overpayments.","searchable_name":"Glenn Solomon","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":34,"capability_group_featured":null,"home_page_featured":null}]}}